In another aspect, the present disclosure relates to a compound, or a pharmaceutically acceptable salt thereof, wherein said compound is selected from the group consisting of:

4-{4-[(ethylsulfonyl)amino]-2-[1-methyl-6-oxo-4-(2,2,2-trifluoroethoxy)-1,6-dihydropyridin-3-yl]phenoxy}benzamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-2-oxo-1-phenylpyrrolidine-3-carboxamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-3,3-dimethylbutanamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-4-(phenoxymethyl)benzamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-4-methylpentanamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-1-phenylcyclopropanecarboxamide;

4-(acetylamino)-N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]benzamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-4-(propan-2-yloxy)benzamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-2-(2-phenylethyl)benzamide;

4-(diethylamino)-N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]benzamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]biphenyl-4-carboxamide;

5-{2-(2,4-difluorophenoxy)-5-[(2,2-dimethylpropyl)amino]phenyl}-4-ethoxy-1-methylpyridin-2(1H)-one;

5-{2-(2,4-difluorophenoxy)-5-[(3,3-dimethylbutyl)amino]phenyl}-4-ethoxy-1-methylpyridin-2(1H)-one;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-4-(methylsulfonyl)benzenesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-4-(trifluoromethoxy)benzenesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]biphenyl-4-sulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-1-[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-1-phenylmethanesulfonamide;

5-[2-(cyclopropylmethoxy)-4-(3-methyl-1H-pyrazol-5-yl)phenyl]-1-methylpyridin-2(1H)-one;

5-{2-[2-(but-3-en-1-yn-1-yl)phenoxy]-5-(ethylsulfonyl)phenyl}-4-hydroxy-1-methylpyridin-2(1H)-one;

4-chloro-5-{5-(ethylsulfonyl)-2-[2-(3-hydroxyprop-1-yn-1-yl)phenoxy]phenyl}-1-methylpyridin-2(1H)-one;

N-[4-(2,4-difluorophenoxy)-3-(1-methyl-4-{[4-(morpholin-4-ylmethyl)benzyl]oxy}-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-{4-(2,4-difluorophenoxy)-3-[1-methyl-4-(oxetan-3-yloxy)-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

4-(2,4-difluorophenoxy)-5-[2-(2,4-difluorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methylpyridin-2(1H)-one;

5-[2-(2,4-difluorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-4-(oxetan-3-yloxy)pyridin-2(1H)-one;

tert-butyl 4-[(5-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)oxy]piperidine-1-carboxylate;

tert-butyl 4-{[5-(2-{4-[1-(tert-butoxycarbonyl)piperidin-4-yl]-2-fluorophenoxy}-5-[(ethylsulfonyl)amino]phenyl)-1-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy}piperidine-1-carboxylate;

N-[4-(2,4-difluorophenoxy)-3-(4-{[trans-4-(dimethylamino)cyclohexyl]oxy}-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-{4-(2,4-difluorophenoxy)-3-[1-methyl-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-{1-methyl-4-[(1-methylpyrrolidin-3-yl)methoxy]-6-oxo-1,6-dihydropyridin-3-yl}phenyl]ethanesulfonamide;

tert-butyl 4-{[(5-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)oxy]methyl}piperidine-1-carboxylate;

tert-butyl 6-[(5-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)oxy]-2-azaspiro[3.3]heptane-2-carboxylate;

N-{3-[4-(2-azaspiro[3.3]hept-6-yloxy)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]-4-(2,4-difluorophenoxy)phenyl}ethanesulfonamide;

5-{2-[(cyclopropylmethyl)amino]-5-(methylsulfonyl)phenyl}-4-[(E)-2-ethoxyethenyl]-1-methylpyridin-2(1H)-one;

N-[3-(4-{[4-(diethylamino)but-2-yn-1-yl]oxy}-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(2,4-difluorophenoxy)phenyl]ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-{1-methyl-6-oxo-4-[(1E)-prop-1-en-1-yl]-1,6-dihydropyridin-3-yl}phenyl]ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-{1-methyl-4-[4-(4-methylpiperazin-1-yl)phenyl]-6-oxo-1,6-dihydropyridin-3-yl}phenyl]ethanesulfonamide;

N-{4-(2,4-difluorophenoxy)-3-[4-(2-hydroxyphenyl)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-{4-(2,4-difluorophenoxy)-3-[4-(4-formylthiophen-3-yl)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-{4-[(1,1-$^{2}H_{2}$)ethyloxy]-1-methyl-6-oxo-1,6-dihydropyridin-3-yl}phenyl]ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-{4-[($^{2}H_{5}$)ethyloxy]-1-methyl-6-oxo-1,6-dihydropyridin-3-yl}phenyl]ethanesulfonamide;

N-[3-{4-[(2,2-difluoro-1-methylcyclopropyl)methoxy]-1-methyl-6-oxo-1,6-dihydropyridin-3-yl}-4-(2,4-difluorophenoxy)phenyl]ethanesulfonamide;

N-{4-[2-fluoro-4-(oxetan-3-yloxy)phenoxy]-3-[1-methyl-4-(oxetan-3-yloxy)-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

5-{2-[(cyclopropylmethyl)amino]-5-(methylsulfonyl)phenyl}-4-[(Z)-2-ethoxyethenyl]-1-methylpyridin-2(1H)-one;

ethyl {5-[2-(cyclopropylmethoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-2-oxo-1,2-dihydropyridin-3-yl}carbamate;

N-{5-[2-(cyclopropylmethoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-2-oxo-1,2-dihydropyridin-3-yl}methanesulfonamide;

5-{2-[(cyclopropylmethyl)amino]-5-(methylsulfonyl)phenyl}-4-ethoxy-1-methylpyridin-2(1H)-one;

5-{2-[(cyclopropylmethyl)amino]-5-(methylsulfonyl)phenyl}-4-[(3-hydroxy-2,3-dimethylbutan-2-yl)oxy]-1-methylpyridin-2(1H)-one;

N-{4-(2,4-difluorophenoxy)-3-[1-methyl-4-(1-methyl-1H-pyrazol-4-yl)-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]naphthalene-1-sulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]benzenesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(1-methyl-4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-{4-(2,4-difluorophenoxy)-3-[1-methyl-6-oxo-4-(1H-pyrazol-1-yl)-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-4-(propan-2-yl)benzenesulfonamide;

4-chloro-N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-2-fluorobenzenesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]propane-1-sulfonamide;

1-(2-chloro-5-fluorophenyl)-N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]methanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-1-(2-fluorophenyl)methanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(5-fluoro-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-[3-{4-[(cyclopropylmethyl)amino]-1-methyl-6-oxo-1,6-dihydropyridin-3-yl}-4-(2,4-difluorophenoxy)phenyl]ethanesulfonamide;

5-[2-(cyclopropylmethoxy)-6-methylphenyl]-1-methylpyridin-2(1H)-one;

3-amino-5-[2-(cyclopropylmethoxy)-5-(ethylsulfonyl)phenyl]-1-methylpyridin-2(1H)-one;

N-[4-(4-cyanophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(1-methyl-6-oxo-4-propyl-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

5-{5-(ethylsulfonyl)-2-[(cis-4-methoxy-4-methylcyclohexyl)oxy]phenyl}-1-methylpyridin-2(1H)-one;

N-{5-[2-(cyclopropylmethoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-2-oxo-1,2-dihydropyridin-3-yl}acetamide;

N-{3-[4-(cyclopropylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]-4-(2,4-difluorophenoxy)phenyl}ethanesulfonamide;

N-{4-(2,4-difluorophenoxy)-3-[4-(ethylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

5-[2-(2,4-difluorophenoxy)-5-(propan-2-ylsulfonyl)phenyl]-1-methylpyridin-2(1H)-one;

N-[4-(cyclopropylmethoxy)-2-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-[4-(cyclopropylmethoxy)-2-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-{3-[4-(cyclobutyloxy)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]-4-(2,4-difluorophenoxy)phenyl}ethanesulfonamide;

5-{2-[(2,2-difluorocyclopropyl)methoxy]-5-(ethylsulfonyl)phenyl}-4-ethoxy-1-methylpyridin-2(1H)-one;

5-[2-(2,4-difluorophenoxy)-5-(propan-2-ylsulfonyl)phenyl]-4-ethoxy-1-methylpyridin-2(1H)-one;

5-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-4-ethoxy-1-methylpyridin-2(1H)-one;

5-[5-(cyclopropylsulfonyl)-2-(2,4-difluorophenoxy)phenyl]-4-ethoxy-1-methylpyridin-2(1H)-one;

N-{4-(2,4-difluorophenoxy)-3-[4-(3-hydroxy-3-methylbutoxy)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

5-[2-(cyclopropylamino)-5-(ethylsulfonyl)phenyl]-4-ethoxy-1-methylpyridin-2(1H)-one;

N-{4-(4-cyanophenoxy)-3-[1-methyl-6-oxo-4-(2,2,2-trifluoroethoxy)-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

5-[2-(2,4-difluorophenoxy)-5-(ethylsulfonyl)phenyl]-4-ethoxy-1-methylpyridin-2(1H)-one;

N-{4-(2,4-difluorophenoxy)-3-[4-(2-hydroxy-2-methylpropoxy)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

4-ethoxy-5-{5-(ethylsulfonyl)-2-[4-(trifluoromethoxy)phenoxy]phenyl}-1-methylpyridin-2(1H)-one;

4-[2-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(ethylsulfonyl)phenoxy]benzonitrile;

5-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)methyl]phenyl}-4-ethoxy-1-methylpyridin-2(1H)-one;

5-{2-(2,4-difluorophenoxy)-5-[2-(ethylsulfonyl)propan-2-yl]phenyl}-4-ethoxy-1-methylpyridin-2(1H)-one;

N-[4-(cyclopropylmethoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

4-chloro-5-[2-(2,4-difluorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methylpyridin-2(1H)-one;

N-[4-(2-cyclopropylethoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-[4-(cyclobutyloxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-{4-[(4,4-difluorocyclohexyl)oxy]-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl}ethanesulfonamide;

N-{3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-[4-(trifluoromethyl)phenoxy]phenyl}ethanesulfonamide;

N-{3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-[4-(trifluoromethoxy)phenoxy]phenyl}ethanesulfonamide;

ethyl 4-{2-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-[(ethylsulfonyl)amino]phenoxy}piperidine-1-carboxylate;

N-{4-[(1-acetylpiperidin-4-yl)oxy]-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl}ethanesulfonamide;

N-{3-[4-(1-benzyl-1H-pyrazol-4-yl)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]-4-(2,4-difluorophenoxy)phenyl}ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-{1-methyl-4-[1-(2-methylpropyl)-1*H*-pyrazol-4-yl]-6-oxo-1,6-dihydropyridin-3-yl}phenyl]ethanesulfonamide;

N-{4-(2,4-difluorophenoxy)-3-[4-(furan-2-yl)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-{4-(2,4-difluorophenoxy)-3-[4-(furan-3-yl)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-[4-(2,3-dihydro-1H-inden-2-yloxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

tert-butyl (trans-4-{2-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-[(ethylsulfonyl)amino]phenoxy}cyclohexyl)carbamate;

N-[3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(4-fluorophenoxy)phenyl]ethanesulfonamide;

5-[2-(cyclopropylmethoxy)-5-(2,3-dihydro-1H-indol-1-ylsulfonyl)phenyl]-4-ethoxy-1-methylpyridin-2(1H)-one;

4-[2-(2,4-difluorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-5-(2,2,2-trifluoroethoxy)pyridin-2(1H)-one;

N-{4-(2,4-difluorophenoxy)-3-[1-methyl-6-oxo-4-(piperidin-4-ylmethoxy)-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-[4-(4-chlorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-[4-(3,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-[3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(3,4,5-trifluorophenoxy)phenyl]ethanesulfonamide;

N-[4-(4-chloro-2-fluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-[4-(4-chloro-2,6-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-[3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(pyridin-3-yloxy)phenyl]ethanesulfonamide;

5-[5-amino-2-(2,4-difluorophenoxy)phenyl]-4-ethoxy-1-methylpyridin-2(1H)-one;

N-{4-(2,4-difluorophenoxy)-3-[1-methyl-4-(5-methylthiophen-2-yl)-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-[4-(4-cyano-2-fluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

5-{2-[(2,4-difluorobenzyl)amino]-5-(methylsulfonyl)phenyl}-4-ethoxy-1-methylpyridin-2(1H)-one;

N-[3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-({1-[4-(trifluoromethyl)phenyl]piperidin-4-yl}oxy)phenyl]ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-1,3-thiazole-5-carboxamide;

2,5-dichloro-N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]benzamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-4-(propan-2-yl)benzamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-5-methylpyrazine-2-carboxamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]pyridine-2-carboxamide;

4-tert-butyl-N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]benzenesulfonamide;

2,4-dichloro-N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]benzenesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]naphthalene-2-sulfonamide;

5-[2-(2,4-difluorophenoxy)-5-(2,3-dihydro-1H-indol-1-ylsulfonyl)phenyl]-4-ethoxy-1-methylpyridin-2(1H)-one; and

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-N-methyl-1-phenylmethanesulfonamide.

In another aspect, the present disclosure relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound as described above, or a pharmaceutically acceptable acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.

In another aspect, the present disclosure relates to the use of a compound as described above, or a pharmaceutically acceptable acceptable salt thereof, in the manufacture of a medicament for treating cancer.

In another aspect, the present disclosure relates to the use of a compound as described above, or a pharmaceutically acceptable acceptable salt thereof, in the manufacture of a medicament for treating a disease or condition selected from the group consisting of: Addison's disease, acute gout, ankylosing spondylitis, asthma, atherosclerosis, Behcet's disease, bullous skin diseases, chronic obstructive pulmonary disease (COPD), Crohn's disease,dermatitis, eczema,giant cell arteritis, glomerulonephritis, hepatitis, hypophysitis, inflammatory bowel disease,), Kawasaki disease, lupus nephritis, multiple sclerosis, myocarditis,myositis, nephritis, organ transplant rejection, osteoarthritis, pancreatitis, pericarditis, Polyarteritis nodosa, pneumonitis, primary biliary cirrhosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, scleritis, sclerosing cholangitis, sepsis systemic lupus

erythematosus, Takayasu's Arteritis, toxic shock, thyroiditis, type I diabetes, ulcerative colitis, uveitis, vitiligo, vasculitis, and Wegener's granulomatosis.

In another aspect, the present disclosure relates to the use of a compound as described above, or a pharmaceutically acceptable acceptable salt thereof, in the manufacture of a medicament for treating AIDS.

In another aspect, the present disclosure relates to the use of a compound as described above, or a pharmaceutically acceptable acceptable salt thereof, for use in treating obesity.

In another aspect, the present disclosure relates to the use of a compound as described above, or a pharmaceutically acceptable acceptable salt thereof, in the manufacture of a medicament for treating type II diabetes.

In another aspect, the present disclosure relates to the use of a compound as described above, or a pharmaceutically acceptable acceptable salt thereof, in the manufacture of a medicament for treating an acute kidney disease or condition, wherein said acute kidney disease or condition is selected from the group consisting of: ischemia-reperfusion induced kidney disease, cardiac and major surgery induced kidney disease, percutaneous coronary intervention induced kidney disease, radio-contrast agent induced kidney disease, sepsis induced kidney disease, pneumonia induced kidney disease, and drug toxicity induced kidney disease.

In another aspect, the present disclosure relates to the use of a compound as described above, or a pharmaceutically acceptable acceptable salt thereof, in the manufacture of a medicament for treating a chronic kidney disease or condition, wherein said disease or condition is selected from the group consisting of: diabetic nephropathy, hypertensive nephropathy, HIV-associated nephropathy, glomerulonephritis, lupus nephritis, IgA nephropathy, focal segmental glomerulosclerosis, membranous glomerulonephritis, minimal change disease, polycystic kidney disease and tubular interstitial nephritis.

In another aspect, the present disclosure relates to pharmaceutical compositions comprising a pharmaceutically acceptable exicipient and a therapeutically effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof.

In another aspect, the present disclosure relates to methods of treating cancer in a subject comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable acceptable salt thereof, to a subject in need thereof. In certain embodiments, the cancer is selected from the group consisting of: acoustic neuroma, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia

(monocytic, myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute t-cell leukemia, basal cell carcinoma, bile duct carcinoma, bladder cancer, brain cancer, breast cancer, bronchogenic carcinoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myelocytic (granulocytic) leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, diffuse large B-cell lymphoma, dysproliferative changes (dysplasias and metaplasias), embryonal carcinoma, endometrial cancer, endotheliosarcoma, ependymoma, epithelial carcinoma, erythroleukemia, esophageal cancer, estrogen-receptor positive breast cancer, essential thrombocythemia, Ewing's tumor, fibrosarcoma, follicular lymphoma, germ cell testicular cancer, glioma, glioblastoma, gliosarcoma, heavy chain disease, hemangioblastoma, hepatoma, hepatocellular cancer, hormone insensitive prostate cancer, leiomyosarcoma, leukemia, liposarcoma, lung cancer, lymphagioendotheliosarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma (Hodgkin's and non-Hodgkin's), malignancies and hyperproliferative disorders of the bladder, breast, colon, lung, ovaries, pancreas, prostate, skin and uterus, lymphoid malignancies of T-cell or B-cell origin, leukemia, lymphoma, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, NUT midline carcinoma (NMC), non-small cell lung cancer, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinomas, papillary carcinoma, pinealoma, polycythemia vera, prostate cancer, rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous gland carcinoma, seminoma, skin cancer, small cell lung carcinoma, solid tumors (carcinomas and sarcomas), small cell lung cancer, stomach cancer, squamous cell carcinoma, synovioma, sweat gland carcinoma, thyroid cancer, Waldenström's macroglobulinemia, testicular tumors, uterine cancer and Wilms' tumor. In

CLAIMS:

1. A compound, or a pharmaceutically acceptable salt thereof, wherein said compound is selected from the group consisting of:

4-{4-[(ethylsulfonyl)amino]-2-[1-methyl-6-oxo-4-(2,2,2-trifluoroethoxy)-1,6-dihydropyridin-3-yl]phenoxy}benzamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-2-oxo-1-phenylpyrrolidine-3-carboxamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-3,3-dimethylbutanamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-4-(phenoxymethyl)benzamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-4-methylpentanamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-1-phenylcyclopropanecarboxamide;

4-(acetylamino)-N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]benzamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-4-(propan-2-yloxy)benzamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-2-(2-phenylethyl)benzamide;

4-(diethylamino)-N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]benzamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]biphenyl-4-carboxamide;

5-{2-(2,4-difluorophenoxy)-5-[(2,2-dimethylpropyl)amino]phenyl}-4-ethoxy-1-methylpyridin-2(1H)-one;

5-{2-(2,4-difluorophenoxy)-5-[(3,3-dimethylbutyl)amino]phenyl}-4-ethoxy-1-methylpyridin-2(1H)-one;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-4-(methylsulfonyl)benzenesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-4-(trifluoromethoxy)benzenesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]biphenyl-4-sulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-1-[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-1-phenylmethanesulfonamide;

5-[2-(cyclopropylmethoxy)-4-(3-methyl-1H-pyrazol-5-yl)phenyl]-1-methylpyridin-2(1H)-one;

5-{2-[2-(but-3-en-1-yn-1-yl)phenoxy]-5-(ethylsulfonyl)phenyl}-4-hydroxy-1-methylpyridin-2(1H)-one;

4-chloro-5-{5-(ethylsulfonyl)-2-[2-(3-hydroxyprop-1-yn-1-yl)phenoxy]phenyl}-1-methylpyridin-2(1H)-one;

N-[4-(2,4-difluorophenoxy)-3-(1-methyl-4-{[4-(morpholin-4-ylmethyl)benzyl]oxy}-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-{4-(2,4-difluorophenoxy)-3-[1-methyl-4-(oxetan-3-yloxy)-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

4-(2,4-difluorophenoxy)-5-[2-(2,4-difluorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methylpyridin-2(1H)-one;

5-[2-(2,4-difluorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-4-(oxetan-3-yloxy)pyridin-2(1H)-one;

tert-butyl 4-[(5-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)oxy]piperidine-1-carboxylate;

tert-butyl 4-{[5-(2-{4-[1-(tert-butoxycarbonyl)piperidin-4-yl]-2-fluorophenoxy}-5-[(ethylsulfonyl)amino]phenyl)-1-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy}piperidine-1-carboxylate;

N-[4-(2,4-difluorophenoxy)-3-(4-{[trans-4-(dimethylamino)cyclohexyl]oxy}-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-{4-(2,4-difluorophenoxy)-3-[1-methyl-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-{1-methyl-4-[(1-methylpyrrolidin-3-yl)methoxy]-6-oxo-1,6-dihydropyridin-3-yl}phenyl]ethanesulfonamide;

tert-butyl 4-{[(5-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)oxy]methyl}piperidine-1-carboxylate;

tert-butyl 6-[(5-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)oxy]-2-azaspiro[3.3]heptane-2-carboxylate;

N-{3-[4-(2-azaspiro[3.3]hept-6-yloxy)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]-4-(2,4-difluorophenoxy)phenyl}ethanesulfonamide;

5-{2-[(cyclopropylmethyl)amino]-5-(methylsulfonyl)phenyl}-4-[(E)-2-ethoxyethenyl]-1-methylpyridin-2(1H)-one;

N-[3-(4-{[4-(diethylamino)but-2-yn-1-yl]oxy}-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(2,4-difluorophenoxy)phenyl]ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-{1-methyl-6-oxo-4-[(1E)-prop-1-en-1-yl]-1,6-dihydropyridin-3-yl}phenyl]ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-{1-methyl-4-[4-(4-methylpiperazin-1-yl)phenyl]-6-oxo-1,6-dihydropyridin-3-yl}phenyl]ethanesulfonamide;

N-{4-(2,4-difluorophenoxy)-3-[4-(2-hydroxyphenyl)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-{4-(2,4-difluorophenoxy)-3-[4-(4-formylthiophen-3-yl)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-{4-[(1,1-$^{2}H_{2}$)ethyloxy]-1-methyl-6-oxo-1,6-dihydropyridin-3-yl}phenyl]ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-{4-[($^{2}H_{5}$)ethyloxy]-1-methyl-6-oxo-1,6-dihydropyridin-3-yl}phenyl]ethanesulfonamide;

N-[3-{4-[(2,2-difluoro-1-methylcyclopropyl)methoxy]-1-methyl-6-oxo-1,6-dihydropyridin-3-yl}-4-(2,4-difluorophenoxy)phenyl]ethanesulfonamide;

N-{4-[2-fluoro-4-(oxetan-3-yloxy)phenoxy]-3-[1-methyl-4-(oxetan-3-yloxy)-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

5-{2-[(cyclopropylmethyl)amino]-5-(methylsulfonyl)phenyl}-4-[(Z)-2-ethoxyethenyl]-1-methylpyridin-2(1H)-one;

ethyl {5-[2-(cyclopropylmethoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-2-oxo-1,2-dihydropyridin-3-yl}carbamate;

N-{5-[2-(cyclopropylmethoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-2-oxo-1,2-dihydropyridin-3-yl}methanesulfonamide;

5-{2-[(cyclopropylmethyl)amino]-5-(methylsulfonyl)phenyl}-4-ethoxy-1-methylpyridin-2(1H)-one;

5-{2-[(cyclopropylmethyl)amino]-5-(methylsulfonyl)phenyl}-4-[(3-hydroxy-2,3-dimethylbutan-2-yl)oxy]-1-methylpyridin-2(1H)-one;

N-{4-(2,4-difluorophenoxy)-3-[1-methyl-4-(1-methyl-1H-pyrazol-4-yl)-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]naphthalene-1-sulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]benzenesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(1-methyl-4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-{4-(2,4-difluorophenoxy)-3-[1-methyl-6-oxo-4-(1H-pyrazol-1-yl)-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-4-(propan-2-yl)benzenesulfonamide;

4-chloro-N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-2-fluorobenzenesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]propane-1-sulfonamide;

1-(2-chloro-5-fluorophenyl)-N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]methanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-1-(2-fluorophenyl)methanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(5-fluoro-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-[3-{4-[(cyclopropylmethyl)amino]-1-methyl-6-oxo-1,6-dihydropyridin-3-yl}-4-(2,4-difluorophenoxy)phenyl]ethanesulfonamide;

5-[2-(cyclopropylmethoxy)-6-methylphenyl]-1-methylpyridin-2(1H)-one;

3-amino-5-[2-(cyclopropylmethoxy)-5-(ethylsulfonyl)phenyl]-1-methylpyridin-2(1H)-one;

N-[4-(4-cyanophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(1-methyl-6-oxo-4-propyl-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

5-{5-(ethylsulfonyl)-2-[(cis-4-methoxy-4-methylcyclohexyl)oxy]phenyl}-1-methylpyridin-2(1H)-one;

N-{5-[2-(cyclopropylmethoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-2-oxo-1,2-dihydropyridin-3-yl}acetamide;

N-{3-[4-(cyclopropylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]-4-(2,4-difluorophenoxy)phenyl}ethanesulfonamide;

N-{4-(2,4-difluorophenoxy)-3-[4-(ethylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

5-[2-(2,4-difluorophenoxy)-5-(propan-2-ylsulfonyl)phenyl]-1-methylpyridin-2(1H)-one;

N-[4-(cyclopropylmethoxy)-2-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-[4-(cyclopropylmethoxy)-2-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-{3-[4-(cyclobutyloxy)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]-4-(2,4-difluorophenoxy)phenyl}ethanesulfonamide;

5-{2-[(2,2-difluorocyclopropyl)methoxy]-5-(ethylsulfonyl)phenyl}-4-ethoxy-1-methylpyridin-2(1H)-one;

5-[2-(2,4-difluorophenoxy)-5-(propan-2-ylsulfonyl)phenyl]-4-ethoxy-1-methylpyridin-2(1H)-one;

5-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-4-ethoxy-1-methylpyridin-2(1H)-one;

5-[5-(cyclopropylsulfonyl)-2-(2,4-difluorophenoxy)phenyl]-4-ethoxy-1-methylpyridin-2(1H)-one;

N-{4-(2,4-difluorophenoxy)-3-[4-(3-hydroxy-3-methylbutoxy)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

5-[2-(cyclopropylamino)-5-(ethylsulfonyl)phenyl]-4-ethoxy-1-methylpyridin-2(1H)-one;

N-{4-(4-cyanophenoxy)-3-[1-methyl-6-oxo-4-(2,2,2-trifluoroethoxy)-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

5-[2-(2,4-difluorophenoxy)-5-(ethylsulfonyl)phenyl]-4-ethoxy-1-methylpyridin-2(1H)-one;

N-{4-(2,4-difluorophenoxy)-3-[4-(2-hydroxy-2-methylpropoxy)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

4-ethoxy-5-{5-(ethylsulfonyl)-2-[4-(trifluoromethoxy)phenoxy]phenyl}-1-methylpyridin-2(1H)-one;

4-[2-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(ethylsulfonyl)phenoxy]benzonitrile;

5-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)methyl]phenyl}-4-ethoxy-1-methylpyridin-2(1H)-one;

5-{2-(2,4-difluorophenoxy)-5-[2-(ethylsulfonyl)propan-2-yl]phenyl}-4-ethoxy-1-methylpyridin-2(1H)-one;

N-[4-(cyclopropylmethoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

4-chloro-5-[2-(2,4-difluorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methylpyridin-2(1H)-one;

N-[4-(2-cyclopropylethoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-[4-(cyclobutyloxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-{4-[(4,4-difluorocyclohexyl)oxy]-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl}ethanesulfonamide;

N-{3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-[4-(trifluoromethyl)phenoxy]phenyl}ethanesulfonamide;

N-{3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-[4-(trifluoromethoxy)phenoxy]phenyl}ethanesulfonamide;

ethyl 4-{2-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-[(ethylsulfonyl)amino]phenoxy}piperidine-1-carboxylate;

N-{4-[(1-acetylpiperidin-4-yl)oxy]-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl}ethanesulfonamide;

N-{3-[4-(1-benzyl-1H-pyrazol-4-yl)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]-4-(2,4-difluorophenoxy)phenyl}ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-{1-methyl-4-[1-(2-methylpropyl)-1*H*-pyrazol-4-yl]-6-oxo-1,6-dihydropyridin-3-yl}phenyl]ethanesulfonamide;

N-{4-(2,4-difluorophenoxy)-3-[4-(furan-2-yl)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-{4-(2,4-difluorophenoxy)-3-[4-(furan-3-yl)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-[4-(2,3-dihydro-1H-inden-2-yloxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

tert-butyl (trans-4-{2-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-[(ethylsulfonyl)amino]phenoxy}cyclohexyl)carbamate;

N-[3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(4-fluorophenoxy)phenyl]ethanesulfonamide;

5-[2-(cyclopropylmethoxy)-5-(2,3-dihydro-1H-indol-1-ylsulfonyl)phenyl]-4-ethoxy-1-methylpyridin-2(1H)-one;

4-[2-(2,4-difluorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-5-(2,2,2-trifluoroethoxy)pyridin-2(1H)-one;

N-{4-(2,4-difluorophenoxy)-3-[1-methyl-6-oxo-4-(piperidin-4-ylmethoxy)-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-[4-(4-chlorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-[4-(3,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-[3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(3,4,5-trifluorophenoxy)phenyl]ethanesulfonamide;

N-[4-(4-chloro-2-fluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-[4-(4-chloro-2,6-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-[3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(pyridin-3-yloxy)phenyl]ethanesulfonamide;

5-[5-amino-2-(2,4-difluorophenoxy)phenyl]-4-ethoxy-1-methylpyridin-2(1H)-one;

N-{4-(2,4-difluorophenoxy)-3-[1-methyl-4-(5-methylthiophen-2-yl)-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-[4-(4-cyano-2-fluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

5-{2-[(2,4-difluorobenzyl)amino]-5-(methylsulfonyl)phenyl}-4-ethoxy-1-methylpyridin-2(1H)-one;

N-[3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-({1-[4-(trifluoromethyl)phenyl]piperidin-4-yl}oxy)phenyl]ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-1,3-thiazole-5-carboxamide;

2,5-dichloro-N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]benzamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-4-(propan-2-yl)benzamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-5-methylpyrazine-2-carboxamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]pyridine-2-carboxamide;

4-tert-butyl-N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]benzenesulfonamide;

2,4-dichloro-N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]benzenesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]naphthalene-2-sulfonamide;

5-[2-(2,4-difluorophenoxy)-5-(2,3-dihydro-1H-indol-1-ylsulfonyl)phenyl]-4-ethoxy-1-methylpyridin-2(1H)-one; and

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-N-methyl-1-phenylmethanesulfonamide.

2. A pharmaceutical composition comprising a therapeutically effective amount of a compound according to claim 1, or a pharmaceutically acceptable acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.

3. Use of a compound according to claim 1, or a pharmaceutically acceptable acceptable salt thereof, in the manufacture of a medicament for treating cancer.

4. The use of claim 3, or a pharmaceutically acceptable salt thereof, wherein the cancer is selected from the group consisting of: acoustic neuroma, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia (monocytic, myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute t-cell leukemia, basal cell carcinoma, bile duct carcinoma, bladder cancer, brain cancer, breast cancer, bronchogenic carcinoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myelocytic (granulocytic) leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, diffuse large B-cell lymphoma, dysproliferative changes (dysplasias and metaplasias), embryonal carcinoma, endometrial cancer,

endotheliosarcoma, ependymoma, epithelial carcinoma, erythroleukemia, esophageal cancer, estrogen-receptor positive breast cancer, essential thrombocythemia, Ewing's tumor, fibrosarcoma, follicular lymphoma, germ cell testicular cancer, glioma, glioblastoma, gliosarcoma, heavy chain disease, hemangioblastoma, hepatoma, hepatocellular cancer, hormone insensitive prostate cancer, leiomyosarcoma, leukemia, liposarcoma, lung cancer, lymphagioendotheliosarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma (Hodgkin's and non-Hodgkin's), malignancies and hyperproliferative disorders of the bladder, breast, colon, lung, ovaries, pancreas, prostate, skin and uterus, lymphoid malignancies of T-cell or B-cell origin, leukemia, lymphoma, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, NUT midline carcinoma (NMC), non-small cell lung cancer, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinomas, papillary carcinoma, pinealoma, polycythemia vera, prostate cancer, rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous gland carcinoma, seminoma, skin cancer, small cell lung carcinoma, solid tumors (carcinomas and sarcomas), small cell lung cancer, stomach cancer, squamous cell carcinoma, synovioma, sweat gland carcinoma, thyroid cancer, Waldenström's macroglobulinemia, testicular tumors, uterine cancer and Wilms' tumor.

5. The use of claim 4, or a pharmaceutically acceptable salt thereof, further comprising at least one additional therapeutic agent.

6. Use of a compound according to claim 1, or a pharmaceutically acceptable acceptable salt thereof, in the manufacture of a medicament for treating a disease or condition selected from the group consisting of: Addison's disease, acute gout, ankylosing spondylitis, asthma, atherosclerosis, Behcet's disease, bullous skin diseases, chronic obstructive pulmonary disease (COPD), Crohn's disease,dermatitis, eczema,giant cell arteritis, glomerulonephritis, hepatitis, hypophysitis, inflammatory bowel disease,), Kawasaki disease, lupus nephritis, multiple sclerosis, myocarditis,myositis, nephritis, organ transplant rejection, osteoarthritis, pancreatitis, pericarditis, Polyarteritis nodosa, pneumonitis, primary biliary cirrhosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, scleritis, sclerosing cholangitis, sepsis systemic lupus erythematosus, Takayasu's Arteritis, toxic shock, thyroiditis, type I diabetes, ulcerative colitis, uveitis, vitiligo, vasculitis, and Wegener's granulomatosis.

7. The use of claim 6, or a pharmaceutically acceptable salt thereof, further comprising at least one additional therapeutic agent.

8. Use of a compound according to claim 1, or a pharmaceutically acceptable acceptable salt thereof, in the manufacture of a medicament for treating AIDS.

9. The use of claim 8, or a pharmaceutically acceptable salt thereof, further comprising at least one additional therapeutic agent.

10. Use of a compound according to claim 1, or a pharmaceutically acceptable acceptable salt thereof, for use in treating obesity.

11. The compound of claim 10, or a pharmaceutically acceptable salt thereof, further comprising at least one additional therapeutic agent.

12. Use of a compound according to claim 1, or a pharmaceutically acceptable acceptable salt thereof, in the manufacture of a medicament for treating type II diabetes.

13. The use of claim 12, or a pharmaceutically acceptable salt thereof, further comprising at least one additional therapeutic agent.

14. Use of a compound according to claim 1, or a pharmaceutically acceptable acceptable salt thereof, in the manufacture of a medicament for treating an acute kidney disease or condition, wherein said acute kidney disease or condition is selected from the group consisting of: ischemia-reperfusion induced kidney disease, cardiac and major surgery induced kidney disease, percutaneous coronary intervention induced kidney disease, radio-contrast agent induced kidney disease, sepsis induced kidney disease, pneumonia induced kidney disease, and drug toxicity induced kidney disease.


15. The use of claim 14, or a pharmaceutically acceptable salt thereof, further comprising at least one additional therapeutic agent.

16. Use of a compound according to claim 1, or a pharmaceutically acceptable acceptable salt thereof, in the manufacture of a medicament for treating a chronic kidney disease or condition, wherein said disease or condition is selected from the group consisting of: diabetic nephropathy, hypertensive nephropathy, HIV-associated nephropathy, glomerulonephritis, lupus nephritis, IgA nephropathy, focal segmental glomerulosclerosis, membranous glomerulonephritis, minimal change disease, polycystic kidney disease and tubular interstitial nephritis.

17. The use of claim 16, or a pharmaceutically acceptable salt thereof, further comprising at least one additional therapeutic agent.


CLAIMS:

1. A compound of formula (I), or a pharmaceutically acceptable salt thereof:




I

Wherein J is a group of formula IIa or IIb:



(IIa) or



(IIb);

wherein

R^{1a} is C_1-C_3 alkyl, C_2-C_3 alkylene-OH, or C_1-C_3 haloalkyl;

Y^{1a} is N or CR^{xa}, wherein R^{xa} is H, halo, C_1-C_3 alkyl, -O-C_1-C_3 alkyl, C_1-C_3 haloalkyl, -O-C_1-C_3 haloalkyl, aryl, aryl-C_1-C_3alkylene-OH, aryl-C_1-C_3alkylene-heterocycloalkyl, $C(O)NR^{10}R^{12}$, wherein heterocycloalkyl of aryl-C_1-C_3alkylene-heterocycloalkyl may be substituted with one to three C_1-C_3alkyl,

R^{1b} is H, C_1-C_3 alkyl, C_2-C_3 alkylene-OH, or C_1-C_3 haloalkyl;

Y^{1b} is N or CR^{xb}, wherein R^{xb} is heteroaryl, H, halo, C_1-C_3 alkyl, -O-C_1-C_3 alkyl, C_1-C_3 haloalkyl, -O-C_1-C_3 haloalkyl, aryl, aryl-C_1-C_3alkylene-OH, aryl-C_1-C_3alkylene-heterocycloalkyl, $C(O)NR^{10}R^{12}$, wherein heterocycloalkyl of aryl-C_1-C_3alkylene-heterocycloalkyl may be substituted with one to three C_1-C_3alkyl; wherein said heteroaryl may be substituted with one to three groups selected from the group consisting of: C_1-C_6 alkyl, C_1-C_3alkylene-aryl, C_1-C_3alkylene-heteroaryl, C_1-C_3alkylene-heterocycloalkyl, COOH, and COO-C_1-C_4alkyl,

X^{2a} is selected from the group consisting of: H, $-NR^{10}R^{12}$, halo, OH, -O-C_1-C_4 alkyl, aryl, heteroaryl, $-NR^{10}C(O)$-C_1-C_4 alkyl, $NR^{10}C(O)O$-C_1-C_6 alkyl, and $NR^{10}S(O)_2$-C_1-C_6 alkyl;

X^{2b} is C_1-C_3 alkyl, C_2-C_3 alkylene-OH, or C_1-C_3 haloalkyl;

X^{1a} and X^{1b} are each selected from the group consisting of: hydrogen, halo, C_1-C_6 alkyl, C_1-C_4 haloalkyl, C_2-C_4 alkenyl, -C_2-C_4 alkenylene-O-C_1-C_6 alkyl, C_2-C_4 alkynyl, -C_2-C_4 alkynylene-N(C_1-C_6 alkyl)$_2$, -O-C_1-C_6 alkyl, -O-CD_2CH_3, -O-CD_2CD_3, -O-C_3-C_7 cycloalkyl, -O-heterocycloalkyl, -O-aryl, -O-C_1-C_3 alkylene-C_3-C_7 cycloalkyl, -O-C_1-C_3 alkylene-heterocycloalkyl, -O-C_1-C_3 alkylene-aryl, wherein the aryl groups of the -O-aryl and -O-C_1-C_3 alkylene-aryl, the C_3-C_7 cycloalkyl groups of the -O-C_3-C_7 cycloalkyl and -O-C_1-C_3 alkylene-C_3-C_7 cycloalkyl, and the heterocycloalkyl groups of the -O-heterocycloalkyl and -O-C_1-C_3 alkylene-heterocycloalkyl may be substituted with 1, 2, or 3 substituents independently selected from the group consisting of oxo, halo, -CN, C_1-C_6 alkyl, C_1-C_6 haloalkyl, NH_2, N(H)(alkyl), N(alkyl)$_2$, -C(O)OC_1-C_6 alkyl, and -C_1-C_3 alkylene-heterocycloalkyl, -O-C_1-C_4 haloalkyl, OH, -O-C_1-C_6 alkylene-OH, -O-C_1-C_6 alkylene-N(R^{10})$_2$, -O-C_1-C_3 alkylene-C(O)O-C_1-C_4 alkyl, -NR^{10}-C_1-C_6 alkyl, -NR^{10}-C_1-C_6 haloalkyl, -NR^{10}-C(O)OC_1-C_6 alkyl, -NR^{10}-C(O)OC_1-C_6 haloalkyl, -NR^{10}-C(O)$NR^{10}R^{12}$, -NR^{10}-SO_2R^{12}, -NR^{10}-C_3-C_7 cycloalkyl, -NR^{10}-C_1-C_3 alkylene-C_3-C_7 cycloalkyl, C_1-C_4 alkylene-OH, -C_1-C_3 alkylene-C(O)O C_1-C_4 alkyl, C_1-C_3 alkylene-NR^{10}C(O)-C_1-C_4 alkyl, -C_1-C_3 alkylene-C(O)$NR^{10}R^{12}$, -C_2-C_4 alkenylene-C(O)-O-C_1-C_4 alkyl, -C(O)-C_1-C_4 alkyl, C(O)O-C_1-C_4 alkyl, C(O)$NR^{10}R^{12}$, -NR^{10}C(O)-C_1-C_4 alkyl, -NR^{10}-C_1-C_3 alkylene-C(O)-C_1-C_4 alkyl, -NR^{10}-C_1-C_3 alkylene-C(O)O-C_1-C_4 alkyl, -$SO_2NR^{10}R^{12}$, and any of groups i-v:

i) C_3-C_{14} cycloalkyl, which may be substituted with 1 to 3 of R^2, where R^2 is selected from the group consisting of: halo, oxo, CN, -O-C_1-C_4 alkyl, -O-C_1-C_4 haloalkyl, -$NR^{10}R^{12}$, C(O)$NR^{10}R^{12}$, C_1-C_4 alkyl, C_1-C_4 haloalkyl, C(O)-C_1-C_4 alkyl, -C(O)O-C_1-C_4 alkyl, $SO_2NR^{10}R^{12}$, SO_2-C_1-C_4 alkyl, and aryl, wherein said aryl may be substituted with 1 to 3 substituents independently selected from group consisting of: halo, C_1-C_3 alkyl, C(O)-C_1-C_3alkyl, C(O)OH, C(O)$NR^{10}R^{12}$, and heteroaryl;

ii) heterocycloalkenyl, which may be substituted with 1 to 3 of R^2, where R^2 is selected from the group consisting of: halo, oxo, CN, -O-C_1-C_4 alkyl, -O-C_1-C_4 haloalkyl, -$NR^{10}R^{12}$, C(O)$NR^{10}R^{12}$, C_1-C_4 alkyl, C_1-C_4 haloalkyl, C(O)-C_1-C_4 alkyl, -C(O)O-C_1-C_4 alkyl, $SO_2NR^{10}R^{12}$, SO_2-C_1-C_4 alkyl, and aryl, wherein said aryl may be substituted with 1 to 3

substituents independently selected from group consisting of: halo, C_1-C_3 alkyl, C(O)-C_1-C_3alkyl, C(O)OH, C(O)$NR^{10}R^{12}$, and heteroaryl;

iii) heterocycloalkyl, which may be substituted with 1 to 3 of R^3, where R^3 is selected from the group consisting of: halo, oxo, CN, -O-C_1-C_4 alkyl, -O-C_1-C_4 haloalkyl, -$NR^{10}R^{12}$, C(O)$NR^{10}R^{12}$, C_1-C_4 alkyl, C_1-C_4 haloalkyl, C(O)-C_1-C_4 alkyl, -C(O)O-C_1-C_4 alkyl, $SO_2NR^{10}R^{12}$, SO_2-C_1-C_4 alkyl, and aryl, wherein said aryl may be substituted with 1 to 3 substituents independently selected from group consisting of: halo, C_1-C_3 alkyl, C(O)-C_1-C_3alkyl, C(O)OH, C(O)$NR^{10}R^{12}$, and heteroaryl;

iv) heteroaryl, which may be substituted with 1 to 3 of R^4, where R^4 is selected from the group consisting of: , halo, oxo, CN, -O-C_1-C_4 alkyl, -O-C_1-C_4 haloalkyl, -$NR^{10}R^{12}$, -C(O)H, C(O)$NR^{10}R^{12}$, C_1-C_6 alkyl, C_1-C_4 haloalkyl, C_1-C_6 alkylene-heterocycloalkyl, C_1-C_6alkylene-aryl, C_1-C_6 alkylene-heteroaryl, C(O)-C_1-C_4 alkyl, -C(O)O-C_1-C_4 alkyl, $SO_2NR^{10}R^{12}$, SO_2-C_1-C_4 alkyl, -NR^{14}C(O)C_1-C_4-alkyl, heterocycloalkyl, and aryl, wherein said aryl may be substituted with 1 to 3 substituents independently selected from group consisting of: halo, C_1-C_3 alkyl, C(O)-C_1-C_3alkyl, C(O)OH, C(O)$NR^{10}R^{12}$, and heteroaryl,

wherein said heterocycloalkyl or heterocycloalkyl group of C_1-C_6 alkylene-heterocycloalkyl may be substituted with 1 to 3 independently selected C_1-C_3 alkyl groups, and wherein said heteroaryl group of C_1-C_6 alkylene-heteroaryl and said aryl groups of C_1-C_6 alkylene-aryl may be substituted with substituents 1 to 3 groups independently selected from C_1-C_3 alkyl and $NR^{14}R^{16}$;

v) aryl, which may be substituted with 1 to 3 of R^6, where R^6 is selected from the group consisting of: halo, CN, -$NR^{14}R^{16}$, -N(R^{14})C(O)-C_1-C_4 alkyl, -$NR^{14}SO_2$-C_1-C_4 alkyl, C(O)H, C(O)C_1-C_6 alkyl, C(O)heterocycloalkyl, C(O)$NR^{14}R^{16}$, -C_1-C_4 alkylene-$NR^{14}R^{16}$, $SO_2NR^{14}R^{16}$, C(O)OC_1-C_4 alkyl, -SO_2-heterocycloalkyl, -SO_2-C_1-C_6 alkyl, -C_1-C_6 alkyl, -OH, -O-C_1-C_6 alkyl, -C_1-C_6 haloalkyl, -O-C_1-C_6 haloalkyl, -C_1-C_6 alkylene-OH, -C(H)(OH)(C_3-C_7 cycloalkyl), -C(H)(OH)(phenyl), C_2-C_4 alkenylene-OH, -C_1-C_6 alkylene-O-C_1-C_6 alkyl, -C_1-C_6 alkylene-OC(O)-C_1-C_6 alkyl, -C_1-C_6 alkylene-C(O)O-C_1-

C_6 alkyl, -C_1-C_6 alkylene-N(H)SO_2-C_1-C_6 alkyl, -C_1-C_6 alkylene-N(H)C(O)-C_1-C_6 alkyl, -C_1-C_6 alkylene-CN,-C_1-C_6 alkylene-heterocycloalkyl, C_1-C_6 alkylene-aryl, C_1-C_6 alkylene-heteroaryl, heteroaryl, and heterocycloalkyl,

wherein said heterocycloalkyl and said heterocycloalkyl of said C(O)heterocycloalkyl and said C_1-C_6 alkylene-heterocycloalkyl may be substituted with 1 to 3 groups independently selected from the group consisting of C_1-C_6 alkyl, and C_1-C_4 alkylene-aryl,

wherein said heteroaryl and the heteroaryl of said C_1-C_6 alkylene-heteroaryl, and the aryl of said C_1-C_6 alkylene-aryl may be substituted with 1 to 3 groups independently selected from the group consisting of C_1-C_4 alkyl, C_1-C_4 haloalkyl, halo, -C_1-C_3 alkylene-CN, -C_1-C_3 alkylene-OH, -C_1-C_3 alkylene-C(O)O-C_1-C_3 alkyl, -C_1-C_3 alkylene-O-C_1-C_3 alkyl, -C_1-C_3 alkylene-OC(O)-C_1-C_3 alkyl, -C_1-C_3 alkylene-NR^{14}-aryl, C_1-C_3 alkylene-NR^{14}-C(O)-C_1-C_4alkyl, -C_1-C_3 alkylene-$NR^{14}SO_2$-C_1-C_4 alkyl, -C(O)-C_1-C_3 alkyl, and -C(O)-heterocycloalkyl, wherein said heterocycloalkyl of C(O)-heterocycloalkyl may be substituted with 1 to 3 groups independently selected from the group consisting of: C_1-C_6 alkyl, -C(O)-$NHCH_2$-aryl, -CH-(OH)-C_1-C_6 alkyl, -CH(OH)-C_2-C_6 alkenyl, -CH(OH)-C_3-C_7 cycloalkyl, -CH(OH)-phenyl, -C(O)$NR^{14}R^{16}$-C_3-C_{14}cycloalkyl, -C(O)NR^{14}-C_1-C_3 alkylene-$NR^{14}R^{16}$, -C(O)NR^{14}-C_1-C_3 alkylene-CN, -C(O)NR^{14}-C_1-C_3 alkylene-$NR^{14}R^{16}$, -C(O)$NR^{14}R^{16}$, -C(O)NH-C_3-C_{14} cycloalkyl, -C(O)NH-C_1-C_3 alkylene-O-C_1-C_3 alkyl, C(O)NH-C_1-C_3 alkylene-OH, -NR^{14}-C_3-C_{14} cycloalkyl, -NR^{14}-C_1-C_3 alkylene-heterocycloalkyl, -NR^{14}C(O)-C_1-C_4 alkyl, heterocycloalkyl, and heteroaryl, wherein said heterocycloalkyl or heteroaryl may be substituted with 1-3 substituents independently selected from the group consisting of: halo, C_1-C_4 alkyl, C_1-C_4 haloalkyl, and aryl;

where R^{14} and R^{16} are independently selected from the group consisting of: C_1-C_4 alkyl, C_3-C_7-cycloalkyl, -C_1-C_3-alkylene-$NR^{10}R^{12}$, -C_1-C_3-alkylene-OR^{12}, -C_1-C_3-alkylene-CN, aryl, C_3-C_7 cycloalkyl, C_1-C_3-alkylene-aryl, and H,

where $R^{10}$and R^{12} are at each occurrence independently selected from the group consisting of H, C_1-C_6 alkyl, C_1-C_3-alkylene-aryl, C_1-C_3-

alkylene-heteroaryl, C_1-C_3-alkylene-C_3-C_7-cycloalkyl, -C_1-C_3-alkylene-heterocycloalkyl, and C_3-C_7 cycloalkyl;

where X^3 is hydrogen or is L-G, where L is absent or is selected from the group consisting of:

-O-, -O-C_1-C_3 alkylene-, -NR^{30}-, -NR^{30}-C_1-C_3 alkylene-, -C(O)-, -C_1-C_3 alkylene- wherein said C_1-C_3 alkylene may be substituted with one to two substituents independently selected from the group consisting of: OH, -$NR^{20}R^{22}$, -NH-heterocycloalkyl, and -O-C_1-C_3 alkyl, and wherein R^{30} is H, C_1-C_4 alkyl, or C_1-C_4 haloalkyl; and

G is selected from the group consisting of:

aryl, heteroaryl, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, and heterocycloalkyl, wherein G may be substituted with 1 to 3 groups independently selected from the group consisting of halo, CN, OH, -C_1-C_4 alkyl, -C_2-C_4 alkynyl substituted with a C_2-C_4 alkenyl or OH, -C_1-C_4 haloalkyl, -SO_2-R^{32}, -O-R^{32}, -C(O)-R^{32}, -C(O)O-R^{32}, -C(O)$NR^{20}R^{22}$, -$NR^{20}R^{22}$, -NR^{20}C(O)OR^{32}, -NR^{20}C(O)R^{32}, -$NR^{20}SO_2R^{34}$, -NR^{20}C(O)$NR^{36}R^{38}$, -O-heterocycloalkyl, aryl, and heterocycloalkyl, and the aryl and the heterocycloalkyl may be substituted with one to three groups independently selected from the group consisting of halo, CN, OH, -C_1-C_4 alkyl, C(O)OC_1-C_6 alkyl, O-C_1-C_4 haloalkyl, and -C_1-C_4 haloalkyl,

wherein R^{32} is selected from -C_1-C_4 alkyl and -C_1-C_4 haloalkyl,

wherein R^{34} is selected from -C_1-C_4 alkyl and -C_1-C_4 haloalkyl,

wherein R^{36} and R^{38} are independently selected from the group consisting of hydrogen, -C_1-C_4 alkyl, and -C_1-C_3 haloalkyl;

where one of A^1, A^2, A^3, and A^4 is CR^{18}, one of A^1, A^2, A^3, and A^4 is N or CR^{19}, and two of A^1, A^2, A^3, and A^4 are CR^{19}, where R^{19} is independently selected from the group consisting of: H, -OR^{20}, CN, -$NR^{20}R^{22}$, halo, C_1-C_4 alkyl, C_1-C_4 haloalkyl, and SO_2R^{20},

wherein R^{18} is selected from the group consisting of: H, NO_2, CN, C_1-C_3 alkyene-SO_2-C_1-C_6 alkyl, C_1-C_3 alkyene-SO_2-C_1-C_6 haloalkyl, C_1-C_3 alkyene-SO_2-$NR^{20}R^{22}$, -$NR^{20}R^{22}$, -$NHSO_2$-$NR^{20}R^{22}$, -$NR^{40}SO_2$-C_1-C_4 alkyl, -$NR^{40}SO_2$-C_1-C_4 haloalkyl, -$NR^{40}SO_2$-CH_2-C(O)OH, -$NR^{40}SO_2$-CH_2-C(O)OC_1-C_4 alkyl, -$NR^{40}SO_2$-C_3-C_7 cycloalkyl, -$NR^{40}SO_2$-aryl, -

$NR^{40}SO_2$-heteroaryl, -$NR^{40}SO_2$-C_1-C_3 alkylene-C_3-C_{14} cycloalkyl, -$NR^{40}SO_2$-C_1-C_3 alkylene-heterocycloalkyl, -$NR^{40}SO_2$-C_1-C_3 alkylene-heteroaryl, -$NR^{40}SO_2$-C_1-C_3 alkylene-aryl, -SO_2-$NR^{40}R^{42}$, -SO_2-NR^{40}-C_1-C_4 haloalkyl, -SO_2-NR^{40}-C_3-C_{14} cycloalkyl, -SO_2-NR^{40}-$C(O)NR^{20}R^{22}$, -SO_2-NR^{40}-heterocycloalkyl, -SO_2-NR^{40}-heteroaryl, -SO_2-NR^{40}-aryl, -SO_2-C_1-C_6 alkyl, -SO_2-C_1-C_6 haloalkyl, -SO_2-C_3-C_{14} cycloalkyl, -SO_2-heterocycloalkyl, -SO_2-heteroaryl, -SO_2-aryl, -$NR^{40}SO_2$-$NR^{20}R^{22}$, -$NR^{40}C(O)$-C_1-C_6 alkyl, -$NR^{40}C(O)NH$-C_1-C_4 alkyl, -$NR^{40}C(O)$-heteroaryl, -$NR^{40}C(O)$-heterocycloalkyl, -$NR^{40}C(O)$-aryl, -$NR^{40}C(O)$-C_3-C_{14} cycloalkyl, -$NR^{40}C(O)O$-C_1-C_4 alkyl, -$NR^{40}C(O)O$-heteroaryl, -$NR^{40}C(O)$-CH_2NH-$C(O)O$-C_1-C_4 alkyl, -$NR^{40}C(O)$-$CH_2NR^{20}R^{22}$, -$C(O)CH_2$-$NR^{20}R^{22}$, -$C(O)NR^{20}R^{22}$, $C(O)OH$, -C_1-C_3 alkylene-NR^{40}-$C(O)$-C_1-C_4 alkyl, -C_1-C_3 alkylene-NR^{40}-$C(O)$-C_1-C_3 haloalkyl, -NR^{40}-heteroaryl, C_3-C_{14} cycloalkyl, heterocycloalkyl, heterocycloalkyl-aryl, heteroaryl, aryl, -C_1-C_3 alkylene-cycloalkyl, -C_1-C_3 alkylene-heterocycloalkyl, -C_1-C_3 alkylene-heteroaryl, and -C_1-C_3 alkylene-aryl,

wherein any of the cycloalkyl, C_3-C_7 cycloalkyl, C_3-C_{14} cycloalkyl, heterocycloalkyl, heteroaryl, or aryl groups of R^{18} may be substituted with 1 to 3 of C_1-C_4 alkyl, C_1-C_4 haloalkyl, halo, oxo, -OH, -O-C_1-C_6 alkyl, -O-C_1-C_6 haloalkyl, -OG^1, -$S(O)_2$-C_1-C_6 alkyl, -$N(R^{40})_2$, -$N(R^{40})C(O)C_1$-C_6 alkyl, G^1, -C_1-C_6 alkylene-G^1, or -C_1-C_6 alkylene-OG^1, wherein G^1 is cycloalkyl, heterocycloalkyl, heteroaryl, or aryl, and each G^1 may be substituted with 1 to 3 of oxo, C_1-C_4 alkyl, C_1-C_4 haloalkyl, or halo,

wherein R^{40} and R^{42} are independently selected from the group consisting of: H and C_1-C_4 alkyl, and

wherein R^{20} and R^{22} are at each occurrence independently selected from the group consisting of: H and C_1-C_6 alkyl.

2. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein A^1 is CR^{19}, A^2 is CR^{18}, A^3 is CR^{19}, and A^4 is CR^{19}.

3. The compound of claim 2, or a pharmaceutically acceptable salt thereof, wherein A^1 is CH, A^2 is CR^{18}, A^3 is CH, and A^4 is CH.

4. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein R^{18} is selected from the group consisting of:

NO_2, C_1-C_3 alkyene-SO_2-C_1-C_6 alkyl, C_1-C_3 alkyene-SO_2-C_1-C_6 haloalkyl, C_1-C_3 alkyene-SO_2-$NR^{20}R^{22}$, -$NR^{20}R^{22}$, -$NHSO_2$-NH_2, -$NR^{40}SO_2$-C_1-C_4 alkyl, -$NR^{40}SO_2$-C_1-C_4 haloalkyl, -$NR^{40}SO_2$-CH_2-C(O)OH, -$NR^{40}SO_2$-CH_2-C(O)OC_1-C_4, -$NR^{40}SO_2$-C_1-C_4 alkyl, -$NR^{40}SO_2$-C_1-C_4 haloalkyl, -$NR^{40}SO_2$-C_3-C_7 cycloalkyl, -$NR^{40}SO_2$-aryl, -$NR^{40}SO_2$-heteroaryl, -$NR^{40}SO_2$-C_1-C_4 alkyl, -$NR^{40}SO_2$-C_1-C_4 haloalkyl, -$NR^{40}SO_2$-C_1-C_3 alkylene-C_3-C_{14} cycloalkyl, -$NR^{40}SO_2$-C_1-C_3 alkylene-heterocycloalkyl, -$NR^{40}SO_2$-C_1-C_3 alkylene-heteroaryl, -$NR^{40}SO_2$-C_1-C_3 alkylene-aryl, -SO_2-$NR^{40}R^{42}$, -SO_2-NR^{40}-C_1-C_4 alkyl, -SO_2-NR^{40}-C_1-C_4 haloalkyl, -SO_2-NR^{40}-C_3-C_{14} cycloalkyl, -SO_2-NR^{40}-C(O)$NR^{20}R^{22}$, -SO_2-NR^{40}-heterocycloalkyl, -SO_2-NR^{40}-heteroaryl, -SO_2-NR^{40}-aryl, -SO_2-C_1-C_6 alkyl, -SO_2-C_1-C_6 haloalkyl, -SO_2-C_3-C_{14} cycloalkyl, -SO_2-heterocycloalkyl, -SO_2-heteroaryl, -SO_2-aryl, -$NR^{40}SO_2$-$NR^{20}R^{22}$, -NR^{40}C(O)-C_1-C_4 alkyl, -NR^{40}C(O)NH-C_1-C_4 alkyl, -NR^{40}C(O)-heteroaryl, -NR^{40}C(O)-aryl, -NR^{40}C(O)O-C_1-C_4 alkyl, -NR^{40}C(O)O-heteroaryl, -NR^{40}C(O)-aryl, -NR^{40}C(O)-CH_2NH-C(O)O-C_1-C_4 alkyl, -C(O)CH_2-$NR^{20}R^{22}$, -C(O)$NR^{20}R^{22}$, C(O)OH, C_1-C_3 alkylene-NR^{40}-C(O)-C_1-C_4 alkyl, C_1-C_3 alkylene-NR^{40}-C(O)-C_1-C_3 haloalkyl, -NR^{40}-heteroaryl, C_3-C_{14} cycloalkyl, heterocycloalkyl, heterocycloalkyl-aryl, heteroaryl, aryl, C_1-C_3 alkylene-cycloalkyl, C_1-C_3 alkylene-heterocycloalkyl, C_1-C_3 alkylene-heteroaryl, and C_1-C_3 alkylene-aryl,

5. The compound of claim 4, or a pharmaceutically acceptable salt thereof, wherein R^{18} is selected from the group consisting of:

$NR^{40}SO_2$-C_1-C_4 alkyl, -$NR^{40}SO_2$-C_1-C_4 haloalkyl, -SO_2-NR^{40}-C_1-C_4 alkyl, -SO_2-NR^{40}-C_1-C_4 haloalkyl, -SO_2-C_1-C_6 alkyl, and -SO_2-C_1-C_6 haloalkyl.

6. The compound of claim 5, or a pharmaceutically acceptable salt thereof, wherein R^{40} is H.

7. The compound of claim 6, or a pharmaceutically acceptable salt thereof, wherein X^3 is L-G and L is -O-, or -O-C_1-C_3 alkylene-.

8. The compound of claim 7, or a pharmaceutically acceptable salt thereof, wherein G is aryl or C_3-C_7 cycloalkyl, wherein G may be substituted with 1 to 3 groups independently selected from the group consisting of CN, OH, -$NR^{20}R^{22}$, -C_1-C_4 haloalkyl, -SO_2-C_1-C_4 alkyl, halo, -C(O)-C_1-C_4-alkyl, -O-C_1-C_4 alkyl, -O-C_1-C_4 haloalkyl, -C_1-C_4 alkyl, -$NR^{20}C(O)R^{32}$, -$NR^{20}SO_2OR^{34}$, -$NR^{20}C(O)NR^{36}R^{38}$,

wherein R^{32} is selected from -C_1-C_4 alkyl and -C_1-C_4 haloalkyl,

wherein R^{34} is selected from -C_1-C_4 alkyl and -C_1-C_4 haloalkyl,

wherein R^{36} and R^{38} are independently selected from the group consisting of hydrogen, -C_1-C_4 alkyl, and -C_1-C_3 haloalkyl.

9. The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein is L is –O-, and –G is phenyl substituted with 1 to 3 halo.

10. The compound of claim 9, or a pharmaceutically acceptable salt thereof, wherein L is –O-, and –G is phenyl substituted with 1 to 3 fluoro.

11. The compound of claim 10, or a pharmaceutically acceptable salt thereof, wherein said phenyl is 2,4-difluoro-phenyl.

12. The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein is L is –O-C_1-C_3 alkyene, and –G is C_3-C_7 cycloalkyl.

13. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein J is IIa, Y^{1a} is N, R^{1a} is methyl, and X^{2a} is hydrogen.

14. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein J is IIa, Y^{1a} is CR^{xa}, wherein R^{xa} is H, R^{1a} is methyl, and X^{2a} is hydrogen.

15. The compound of claim 13 or 14, or a pharmaceutically acceptable salt thereof, wherein X^{1a} is hydrogen.

16. The compound of claim 13 or 14, a pharmaceutically acceptable salt thereof, wherein X^{1a} is selected from the group consisting of:

halo, -O-C_1-C_4 alkyl, and aryl, wherein said aryl may be substituted with 1 to 3 of R^6,

where R^6 is selected from the group consisting of: $NR^{14}SO_2$-C_1-C_4 alkyl, -C_1-C_3 alkylene-$NR^{14}R^{16}$, -C_1-C_6 alkylene-heterocycloalkyl, wherein said heterocycloalkyl of said C_1-C_6 alkylene-heterocycloalkyl may be substituted

with 1 to 3 groups independently selected from the group consisting of C_1-C_6 alkyl and -CH_2-phenyl, wherein said aryl of said C_1-C_6 alkylene-aryl may be substituted with 1 to 3 groups independently selected from the group consisting of: -C_1-C_3 alkylene-OH, and heterocycloalkyl, wherein said heterocycloalkyl may be substituted with 1-3 substituents independently selected from the group consisting of: C_1-C_4 alkyl, C_1-C_4 haloalkyl and aryl.

17. The compound of claim 8, or a pharmaceutically acceptable salt thereof, wherein J is IIb, R^{1b} is hydrogen, X^{2b} is methyl, Y^{1b} is CR^{xb}, and R^{xb} is H.

18. The compound of claim 17, or a pharmaceutically acceptable salt thereof, wherein X^{1b} is hydrogen.

19. The compound of claim 18, or a pharmaceutically acceptable salt thereof, wherein is L is –O-, and G is phenyl substituted with 1 to 3 halo.

20. The compound of claim 19, or a pharmaceutically acceptable salt thereof, wherein G is phenyl substituted with 1 to 3 fluoro.

21. The compound of claim 20, or a pharmaceutically acceptable salt thereof, wherein said phenyl is 2,4-difluoro-phenyl.

22. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein X^3 is L-G, L is –NR^{30}- or - NR^{30}-C_1-C_3 alkylene-, and R^{30} is H.


23. The compound of claim 19, or a pharmaceutically acceptable salt thereof, wherein X^{1b} is H, and R^{18} is $NR^{40}SO_2C_1$-C_4 alkyl.

24. The compound of claim 3, or a pharmaceutically acceptable salt thereof, wherein J is IIa, R^{1a} is methyl, Y^{1a} is N or CH, X^{2a} is H or halo, X^3 is L-G, L is –O- or –O-C_1-C_3 alkylene-, G is phenyl or C_3-C_7 cycloalkyl, wherein G is optionally substituted with 1 to 3 halo, and R^{18} is selected from the group consisting of H, $NR^{40}SO_2$-C_1-C_4 alkyl, -$NR^{40}SO_2$-C_1-C_4 haloalkyl, -SO_2-$NR^{40}R^{42}$, -SO_2-NR^{40}-C_1-C_4 haloalkyl, -SO_2-C_1-C_6 alkyl, and -SO_2-C_1-C_6 haloalkyl.

25. The compound of claim 24, or a pharmaceutically acceptable salt thereof, wherein R^{18} is selected from the group consisting of H, $NR^{40}SO_2$-C_1-C_4 alkyl, and -SO_2-C_1-C_6 alkyl, and X^{1a} is selected from the group consisting of H, -O-C_1-C_6 alkyl, -O-C_1-C_4 haloalkyl, optionally substituted phenyl, optionally substituted heteroaryl, and -O-C_1-


C_3 alkylene-C_3-C_7 cycloalkyl wherein said C_3-C_7 cycloalkyl of -O-C_1-C_3 alkylene-C_3-C_7 cycloalkyl is optionally substituted.

26. The compound of claim 1, or a pharmaceutically acceptable salt thereof,




I

wherein J is a group of formula IIa or IIb:



(IIa) or



(IIb);

wherein

R^{1a} is C_1-C_3 alkyl, C_2-C_3 alkylene-OH, or C_1-C_3 haloalkyl;

Y^{1a} is N or CR^{xa}, wherein R^{xa} is H, halo, C_1-C_3 alkyl, -O-C_1-C_3 alkyl, C_1-C_3 haloalkyl, -O-C_1-C_3 haloalkyl, aryl, aryl-C_1-C_3alkylene-OH, aryl-C_1-C_3alkylene-heterocycloalkyl, $C(O)NR^{10}R^{12}$, wherein heterocycloalkyl of aryl-C_1-C_3alkylene-heterocycloalkyl may be substituted with one to three C_1-C_3alkyl,

R^{1b} is H, C_1-C_3 alkyl, C_2-C_3 alkylene-OH, or C_1-C_3 haloalkyl;

Y^{1b} is N or CR^{xb}, wherein R^{xb} is heteroaryl, H, halo, C_1-C_3 alkyl, -O-C_1-C_3 alkyl, C_1-C_3 haloalkyl, -O-C_1-C_3 haloalkyl, aryl, aryl-C_1-C_3alkylene-OH, aryl-C_1-C_3alkylene-heterocycloalkyl, $C(O)NR^{10}R^{12}$, wherein heterocycloalkyl of aryl-C_1-C_3alkylene-heterocycloalkyl may be substituted with one to three C_1-C_3alkyl; wherein said heteroaryl may be substituted with one to three groups selected from the group consisting of: C_1-C_6 alkyl, C_1-C_3alkylene-aryl, C_1-C_3alkylene-heteroaryl, C_1-C_3alkylene-heterocycloalkyl, COOH, and COO-C_1-C_4alkyl,

X^{2a} is selected from the group consisting of: H, $-NR^{10}R^{12}$, halo, OH, -O-C_1-C_4 alkyl, aryl, heteroaryl, and $-NR^{10}C(O)$-C_1-C_4 alkyl;

X^{2b} is C_1-C_3 alkyl, C_2-C_3 alkylene-OH, or C_1-C_3 haloalkyl;

X^{1a} and X^{1b} are each selected from the group consisting of: hydrogen, halo, C_1-C_6 alkyl, C_1-C_4 haloalkyl, -O-C_1-C_4 alkyl, -O-C_1-C_6 cycloalkyl, -O-C_1-C_3 alkylene-C_3-C_7 cycloalkyl, -O-C_1-C_4 haloalkyl, -O-C_1-C_3 alkylene-heterocycloalkyl, -O-C_1-C_6 alkylene-OH , -O-C_1-C_6 alkylene-$N(R^{10})_2$ -O-C_1-C_3 alkylene-C(O)O-C_1-C_4 alkyl, -NR^{10}-C_1-C_6 alkyl, -NR^{10}-C_1-C_6 haloalkyl, -NR^{10}-C(O)OC_1-C_6 alkyl, -NR^{10}-C(O)OC_1-C_6 haloalkyl, -NR^{10}-C(O)$NR^{10}R^{12}$, -NR^{10}-SO_2R^{12}, -NR^{10}-C_3-C_7 cycloalkyl, -O-C_1-C_3 alkylene-C(O)O-C_1-C_4 alkyl, -NR^{10}-C_1-C_6 alkyl, -NR^{10}-C_1-C_6 haloalkyl, -NR^{10}-C_1-C_3 alkylene-C_3-C_7 cycloalkyl, C_1-C_4 alkylene-OH, -C_1-C_3 alkylene-C(O)O C_1-C_4 alkyl, C_1-C_3 alkylene-NR^{10}C(O)-C_1-C_4 alkyl, -C_1-C_3 alkylene-C(O)$NR^{10}R^{12}$, -C_2-C_4 alkenylene-C(O)-O-C_1-C_4 alkyl, -C(O)-C_1-C_4 alkyl, C(O)O-C_1-C_4 alkyl, C(O)$NR^{10}R^{12}$, -NR^{10}C(O)-C_1-C_4 alkyl, -$NR^{10}SO_2$-C_1-C_4 alkyl, -NR^{10}-C_1-C_3 alkylene-C(O)-C_1-C_4 alkyl, -NR^{10}-C_1-C_3 alkylene-C(O)O-C_1-C_4 alkyl, -$SO_2NR^{10}R^{12}$, and any of groups i-v:

i) C_3-C_{14} cycloalkyl, which may be substituted with 1 to 3 of R^2, where R^2 is selected from the group consisting of: halo, oxo, CN, -O-C_1-C_4 alkyl, -O-C_1-C_4 haloalkyl, -$NR^{10}R^{12}$, C(O)$NR^{10}R^{12}$, C_1-C_4 alkyl, C_1-C_4 haloalkyl, C(O)-C_1-C_4 alkyl, -C(O)O-C_1-C_4 alkyl, $SO_2NR^{10}R^{12}$, SO_2-C_1-C_4 alkyl, and aryl, wherein said aryl may be substituted with 1 to 3 substituents independently selected from group consisting of: halo, C_1-C_3 alkyl, C(O)-C_1-C_3alkyl, C(O)OH, C(O)$NR^{10}R^{12}$, and heteroaryl;

ii) heterocycloalkenyl, which may be substituted with 1 to 3 of R^2, where R^2 is selected from the group consisting of: halo, oxo, CN, -O-C_1-C_4 alkyl, -O-C_1-C_4 haloalkyl, -$NR^{10}R^{12}$, C(O)$NR^{10}R^{12}$, C_1-C_4 alkyl, C_1-C_4 haloalkyl, C(O)-C_1-C_4 alkyl, -C(O)O-C_1-C_4 alkyl, $SO_2NR^{10}R^{12}$, SO_2-C_1-C_4 alkyl, and aryl, wherein said aryl may be substituted with 1 to 3 substituents independently selected from group consisting of: halo, C_1-C_3 alkyl, C(O)-C_1-C_3alkyl, C(O)OH, C(O)$NR^{10}R^{12}$, and heteroaryl;

iii) heterocycloalkyl, which may be substituted with 1 to 3 of R^3, where R^3 is selected from the group consisting of: halo, oxo, CN, -O-C_1-C_4 alkyl, -O-C_1-C_4 haloalkyl, -$NR^{10}R^{12}$, C(O)$NR^{10}R^{12}$, C_1-C_4 alkyl, C_1-C_4 haloalkyl, C(O)-C_1-C_4 alkyl, -C(O)O-C_1-C_4 alkyl, $SO_2NR^{10}R^{12}$, SO_2-C_1-C_4 alkyl, and aryl, wherein said aryl may be substituted with 1 to 3

substituents independently selected from group consisting of: halo, C_1-C_3 alkyl, C(O)-C_1-C_3alkyl, C(O)OH, C(O)$NR^{10}R^{12}$, and heteroaryl;

iv) heteroaryl, which may be substituted with 1 to 3 of R^4, where R^4 is selected from the group consisting of: , halo, oxo, CN, -O-C_1-C_4 alkyl, -O-C_1-C_4 haloalkyl, -$NR^{10}R^{12}$, C(O)$NR^{10}R^{12}$, C_1-C_6 alkyl, C_1-C_4 haloalkyl, C_1-C_6 alkylene-heterocycloalkyl, C_1-C_6alkylene-aryl, C_1-C_6alkylene-heteroaryl, C(O)-C_1-C_4 alkyl, -C(O)O-C_1-C_4 alkyl, $SO_2NR^{10}R^{12}$, SO_2-C_1-C_4 alkyl, -NR^{14}C(O)C_1-C_4-alkyl, NH-C_1-C_4 alkylene-aryl, heterocycloalkyl, and aryl, wherein said aryl may be substituted with 1 to 3 substituents independently selected from group consisting of: halo, C_1-C_3 alkyl, C(O)-C_1-C_3alkyl, C(O)OH, C(O)$NR^{10}R^{12}$, and heteroaryl,

wherein said heterocycloalkyl or heterocycloalkyl group of C_1-C_6 alkylene-heterocycloalkyl may be substituted with 1 to 3 independently selected C_1-C_3 alkyl groups, and wherein said heteroaryl group of C_1-C_6 alkylene-heteroaryl and said aryl groups of C_1-C_6 alkylene-aryl and NH-C_1-C_4 alkylene-aryl may be substituted with substituents 1 to 3 groups independently selected from C_1-C_3 alkyl and $NR^{14}R^{16}$;

v) aryl, which may be substituted with 1 to 3 of R^6, where R^6 is selected from the group consisting of: halo, CN, -$NR^{14}R^{16}$, -$NR^{14}SO_2$-C_1-C_4 alkyl, C(O)H, -C_1-C_4 alkylene-$NR^{14}R^{16}$, $SO_2NR^{14}R^{16}$, C(O)OC_1-C_4 alkyl, -SO_2-heterocycloalkyl, -SO_2-C_1-C_6 alkyl, -C_1-C_6 alkyl, -O-C_1-C_6 alkyl, -C_1-C_6 haloalkyl, -O-C_1-C_6 haloalkyl, -C_1-C_6 alkylene-heterocycloalkyl, C_1-C_6alkylene-aryl, and C_1-C_6alkylene-heteroaryl,

wherein said heterocycloalkyl of said C_1-C_6 alkylene-heterocycloalkyl may be substituted with 1 to 3 groups independently selected from the group consisting of C_1-C_6 alkyl and -CH_2-phenyl, and C_1-C_4 alkylene-aryl,

wherein the heteroaryl of said C_1-C_6 alkylene-heteroaryl and the aryl of said C_1-C_6 alkylene-aryl may be substituted with 1 to 3 groups independently selected from the group consisting of C_1-C_4 alkyl, C_1-C_4 haloalkyl, and halo-C_1-C_3 alkylene-CN, -C_1-C_3 alkylene-OH, -C_1-C_3 alkylene-C(O)O-C_1-C_3 alkyl, -C_1-C_3 alkylene-O-C_1-C_3 alkyl, -C_1-C_3 alkylene-OC(O)-C_1-C_3 alkyl, -C_1-C_3 alkylene-NR^{14}-aryl, C_1-C_3

alkylene-NR^{14}-C(O)-C_1-C_4alkyl, -C_1-C_3 alkylene-$NR^{14}SO_2$-C_1-C_4 alkyl, -C(O)-C_1-C_3 alkylene, and -C(O)-heterocycloalkyl,

wherein said heterocycloalkyl of C(O)-heterocycloalkyl may be substituted with 1 to 3 groups independently selected from the group consisting of: C_1-C_6 alkyl, -C(O)-$NHCH_2$-aryl, -CH-(OH)-C_1-C_6 alkyl, -CH(OH)-C_2-C_6 alkenyl, -CH(OH)-C_3-C_7 cycloalkyl, -CH(OH)-phenyl, -C(O)$NR^{14}R^{16}$-C_3-C_{14}cycloalkyl, -C(O)NR^{14}-C_1-C_3 alkylene-$NR^{14}R^{16}$, -C(O)NR^{14}-C_1-C_3 alkylene-CN, -C(O)NR^{14}-C_1-C_3 alkylene-$NR^{14}R^{16}$, -C(O)$NR^{14}R^{16}$, -C(O)NH-C_3-C_{14} cycloalkyl, -C(O)NH-C_1-C_3 alkylene-O-C_1-C_3 alkyl, C(O)NH-C_1-C_3 alkylene-OH, -NR^{14}-C_3-C_{14} cycloalkyl, -NR^{14}-C_1-C_3 alkylene-heterocycloalkyl, -NR^{14}C(O)-C_1-C_4 alkyl, heterocycloalkyl, and heteroaryl, wherein said heterocycloalkyl or heteroaryl may be substituted with 1-3 substituents independently selected from the group consisting of: halo, C_1-C_4 alkyl, C_1-C_4 haloalkyl and aryl;

where R^{14} and R^{16} are independently selected from the group consisting of: C_1-C_4 alkyl, C_3-C_7-cycloalkyl, -C_1-C_3-alkylene-$NR^{10}R^{12}$, aryl, and H,

where $R^{10}$and R^{12} are at each occurrence independently selected from the group consisting of H, C_1-C_4 alkyl, C_1-C_3-alkylene-aryl, C_1-C_3-alkylene-heteroarylaryl, C_1-C_3-alkylene-C_3-C_7-cycloalkyl, and cyclopropyl;

where X^3 is absent or is L-G, where L is absent or is selected from the group consisting of:

-O-, -O-C_1-C_3 alkylene-, -NR^{30}-, -C(O)-, -C_1-C_3 alkylene-, wherein said C_1-C_3 alkylene may be substituted with one to two substituents independently selected from the group consisting of: OH, -$NR^{20}R^{22}$, -NH-heterocycloalkyl, and -O-C_1-C_3 alkyl, and wherein R^{30} is H or C_1-C_4 alkyl, or C_1-C_4 haloalkyl; and

G is selected from the group consisting of:

aryl, heteroaryl, C_1-C_6 alkyl, C_3-C_7 cycloalkyl, heterocycloalkyl, wherein G may be substituted with 1 to 3 groups independently selected from the group consisting of halo, CN, OH, -C_1-C_4 alkyl, -C_1-C_4 haloalkyl, -SO_2-R^{32}, -O-R^{32}, -C(O)-R^{32}, -C(O)O-R^{32}, -$NR^{20}R^{22}$, -NR^{20}C(O)OR^{32}, -NR^{20}C(O)R^{32}, -$NR^{20}SO_2OR^{34}$, -NR^{20}C(O)$NR^{36}R^{38}$, aryl, and aryl

substituted with one to three groups independently selected from the group consisting of halo, CN, OH, -C_1-C_4 alkyl, and -C_1-C_4 haloalkyl,

wherein R^{32} is selected from -C_1-C_4 alkyl and -C_1-C_4 haloalkyl,

wherein R^{34} is selected from -C_1-C_4 alkyl and -C_1-C_4 haloalkyl,

wherein R^{36} and R^{38} are independently selected from the group consisting of hydrogen, -C_1-C_4 alkyl, and -C_1-C_3 haloalkyl;

where one of A^1, A^2, A^3, and A^4 is CR^{18}, one of A^1, A^2, A^3, and A^4 is N or CR^{19}, and two of A^1, A^2, A^3, and A^4 are CR^{19}, where R^{19} is independently selected from the group consisting of: H, -OR^{20}, CN, -$NR^{20}R^{22}$, halo, C_1-C_4 alkyl, C_1-C_4 haloalkyl, and SO_2R^{20},

wherein R^{18} is selected from the group consisting of: H, NO_2, C_1-C_3 alkyene-SO_2-C_1-C_6 alkyl, C_1-C_3 alkyene-SO_2-C_1-C_6 haloalkyl, C_1-C_3 alkyene-SO_2-$NR^{20}R^{22}$, -$NR^{20}R^{22}$, -$NHSO_2$-NH_2, -$NR^{40}SO_2$-C_1-C_4 alkyl, -$NR^{40}SO_2$-C_1-C_4 haloalkyl, -$NR^{40}SO_2$-CH_2-C(O)OH, -$NR^{40}SO_2$-CH_2-C(O)OC_1-C_4, -$NR^{40}SO_2$-C_1-C_4 alkyl, -$NR^{40}SO_2$-C_1-C_4 haloalkyl, -$NR^{40}SO_2$-C_3-C_7 cycloalkyl, -$NR^{40}SO_2$-aryl, -$NR^{40}SO_2$-heteroaryl, -$NR^{40}SO_2$-C_1-C_4 alkyl, -$NR^{40}SO_2$-C_1-C_4 haloalkyl, -$NR^{40}SO_2$-C_1-C_3 alkylene-C_3-C_{14} cycloalkyl, -$NR^{40}SO_2$-C_1-C_3 alkylene-heterocycloalkyl, -$NR^{40}SO_2$-C_1-C_3 alkylene-heteroaryl, -$NR^{40}SO_2$-C_1-C_3 alkylene-aryl, -SO_2-$NR^{40}R^{42}$, -SO_2-NR^{40}-C_1-C_4 alkyl, -SO_2-NR^{40}-C_1-C_4 haloalkyl, -SO_2-NR^{40}-C_3-C_{14} cycloalkyl, -SO_2-NR^{40}-C(O)$NR^{20}R^{22}$, -SO_2-NR^{40}-heterocycloalkyl, -SO_2-NR^{40}-heteroaryl, -SO_2-NR^{40}-aryl, -SO_2-C_1-C_6 alkyl, -SO_2-C_1-C_6 haloalkyl, -SO_2-C_3-C_{14} cycloalkyl, -SO_2-heterocycloalkyl, -SO_2-heteroaryl, -SO_2-aryl, -$NR^{40}SO_2$-$NR^{20}R^{22}$, -NR^{40}C(O)-C_1-C_4 alkyl, -NR^{40}C(O)NH-C_1-C_4 alkyl, -NR^{40}C(O)-heteroaryl, -NR^{40}C(O)-aryl, -NR^{40}C(O)O-C_1-C_4 alkyl, -NR^{40}C(O)O-heteroaryl, -NR^{40}C(O)-aryl, -NR^{40}C(O)-CH_2NH-C(O)O-C_1-C_4 alkyl, -C(O)CH_2-$NR^{20}R^{22}$, -C(O)$NR^{20}R^{22}$, C(O)OH, C_1-C_3 alkylene-NR^{40}-C(O)-C_1-C_4 alkyl, C_1-C_3 alkylene-NR^{40}-C(O)-C_1-C_3 haloalkyl, -NR^{40}-heteroaryl, C_3-C_{14} cycloalkyl, heterocycloalkyl, heterocycloalkyl-aryl, heteroaryl, aryl, C_1-C_3 alkylene-cycloalkyl, C_1-C_3 alkylene-heterocycloalkyl, C_1-C_3 alkylene-heteroaryl, and C_1-C_3 alkylene-aryl,

wherein any of the cycloalkyl, heterocycloalkyl, heteroaryl, or aryl groups of R^{18} may be substituted with 1 to 3 of C_1-C_4 alkyl, C_1-C_4 haloalkyl or halo,

wherein R^{40} and R^{42} are independently selected from the group consisting of: H and C_1-C_4 alkyl, and

wherein R^{20} and R^{22} are at each occurrence independently selected from the group consisting of: H and C_1-C_4 alkyl.

27. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein said compound is selected from the group consisting of:

1-methyl-5-(2-phenoxyphenyl)pyridin-2(1H)-one;

N-[3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-phenoxyphenyl]methanesulfonamide;

methyl {[3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-phenoxyphenyl]sulfamoyl}acetate;

{[3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-phenoxyphenyl]sulfamoyl}acetic acid;

1-methyl-N-[3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-phenoxyphenyl]-1H-imidazole-4-sulfonamide;

N-[3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-phenoxyphenyl]-1H-imidazole-4-sulfonamide;

2,2,2-trifluoro-N-[3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-phenoxyphenyl]ethanesulfonamide;

N-methyl-N'-[3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-phenoxyphenyl]sulfuric diamide;

N-{3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-[4-(trifluoromethyl)phenoxy]phenyl}methanesulfonamide;

N-[4-(4-fluorophenoxy)-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]methanesulfonamide;

N-[4-(4-chlorophenoxy)-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]methanesulfonamide;

N-[3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(pyridin-3-yloxy)phenyl]methanesulfonamide;

N-[4-(2-chlorophenoxy)-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]methanesulfonamide;

N-{3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-[2-(trifluoromethyl)phenoxy]phenyl}methanesulfonamide;

N-[4-(2-cyanophenoxy)-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]methanesulfonamide;

N-[4-(2-methoxyphenoxy)-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]methanesulfonamide;

N-[4-(2-fluorophenoxy)-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]methanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]methanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-[4-(3,5-difluorophenoxy)-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]methanesulfonamide;

N-[4-(3-chlorophenoxy)-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]methanesulfonamide;

N-{3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-[3-(trifluoromethyl)phenoxy]phenyl}methanesulfonamide;

N-[4-(3-cyanophenoxy)-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]methanesulfonamide;

N-[4-(3-fluorophenoxy)-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]methanesulfonamide;

N-[4-(cyclohexyloxy)-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]methanesulfonamide;

N-[4-(cyclopentyloxy)-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]methanesulfonamide;

N-[3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(tetrahydrofuran-3-yloxy)phenyl]methanesulfonamide;

N-[3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]methanesulfonamide;

N-[3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-phenoxyphenyl]-1H-pyrrole-2-carboxamide;

tert-butyl (2-{[3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-phenoxyphenyl]amino}-2-oxoethyl)carbamate;

N-[3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-phenoxyphenyl]glycinamide;

1-methyl-5-[2-phenoxy-5-(pyridin-2-ylamino)phenyl]pyridin-2(1H)-one;

N-ethyl-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-phenoxybenzenesulfonamide;

3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-phenoxybenzenesulfonamide;

N-[2-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-phenoxyphenyl]methanesulfonamide;

4-methoxy-1-methyl-5-(2-phenoxyphenyl)pyridin-2(1H)-one;

N-[3-(4-methoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-phenoxyphenyl]methanesulfonamide;

N-{4-(2,4-difluorophenoxy)-3-[1-methyl-6-oxo-4-(trifluoromethyl)-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-[3-(4-chloro-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(2,4-difluorophenoxy)phenyl]methanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-methoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]methanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-methoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-{4-[4-(hydroxymethyl)phenyl]-1-methyl-6-oxo-1,6-dihydropyridin-3-yl}phenyl]methanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(1-methyl-4-{4-[(4-methylpiperazin-1-yl)methyl]phenyl}-6-oxo-1,6-dihydropyridin-3-yl)phenyl]methanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-{1-methyl-4-[4-(morpholin-4-yl)phenyl]-6-oxo-1,6-dihydropyridin-3-yl}phenyl]methanesulfonamide;

5-[2-(cyclopropylmethoxy)-5-(ethylsulfonyl)phenyl]-4-methoxy-1-methylpyridin-2(1H)-one;

5-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)amino]phenyl}-N,1-dimethyl-2-oxo-1,2-dihydropyridine-4-carboxamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]methanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-{4-[4-(hydroxymethyl)phenyl]-1-methyl-6-oxo-1,6-dihydropyridin-3-yl}phenyl]ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(1-methyl-4-{4-[(4-methylpiperazin-1-yl)methyl]phenyl}-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-{4-[(dimethylamino)methyl]phenyl}-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

3-chloro-1-methyl-5-(2-phenoxyphenyl)pyridin-2(1H)-one;

N-[3-(5-chloro-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(2,4-difluorophenoxy)phenyl]methanesulfonamide;

N-[3-(5-chloro-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(2,4-difluorophenoxy)phenyl]ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-{1-methyl-4-[4-(morpholin-4-yl)phenyl]-6-oxo-1,6-dihydropyridin-3-yl}phenyl]ethanesulfonamide; sss

4-{4-[(ethylsulfonyl)amino]-2-[1-methyl-6-oxo-4-(2,2,2-trifluoroethoxy)-1,6-dihydropyridin-3-yl]phenoxy}benzamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-2-oxo-1-phenylpyrrolidine-3-carboxamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-3,3-dimethylbutanamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-4-(phenoxymethyl)benzamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-4-methylpentanamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-1-phenylcyclopropanecarboxamide;

4-(acetylamino)-N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]benzamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-4-(propan-2-yloxy)benzamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-2-(2-phenylethyl)benzamide;

4-(diethylamino)-N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]benzamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]biphenyl-4-carboxamide;

5-{2-(2,4-difluorophenoxy)-5-[(2,2-dimethylpropyl)amino]phenyl}-4-ethoxy-1-methylpyridin-2(1H)-one;

5-{2-(2,4-difluorophenoxy)-5-[(3,3-dimethylbutyl)amino]phenyl}-4-ethoxy-1-methylpyridin-2(1H)-one;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-4-(methylsulfonyl)benzenesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-4-(trifluoromethoxy)benzenesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]biphenyl-4-sulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-1-[(1S,4R)-7,7-dimethyl-2-oxobicyclo[2.2.1]hept-1-yl]methanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-1-phenylmethanesulfonamide;

5-[2-(cyclopropylmethoxy)-4-(3-methyl-1H-pyrazol-5-yl)phenyl]-1-methylpyridin-2(1H)-one;

5-{2-[2-(but-3-en-1-yn-1-yl)phenoxy]-5-(ethylsulfonyl)phenyl}-4-hydroxy-1-methylpyridin-2(1H)-one;

4-chloro-5-{5-(ethylsulfonyl)-2-[2-(3-hydroxyprop-1-yn-1-yl)phenoxy]phenyl}-1-methylpyridin-2(1H)-one;

N-[4-(2,4-difluorophenoxy)-3-(1-methyl-4-{[4-(morpholin-4-ylmethyl)benzyl]oxy}-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-{4-(2,4-difluorophenoxy)-3-[1-methyl-4-(oxetan-3-yloxy)-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

4-(2,4-difluorophenoxy)-5-[2-(2,4-difluorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methylpyridin-2(1H)-one;

5-[2-(2,4-difluorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-4-(oxetan-3-yloxy)pyridin-2(1H)-one;

tert-butyl 4-[(5-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)oxy]piperidine-1-carboxylate;

tert-butyl 4-{[5-(2-{4-[1-(tert-butoxycarbonyl)piperidin-4-yl]-2-fluorophenoxy}-5-[(ethylsulfonyl)amino]phenyl)-1-methyl-2-oxo-1,2-dihydropyridin-4-yl]oxy}piperidine-1-carboxylate;

N-[4-(2,4-difluorophenoxy)-3-(4-{[trans-4-(dimethylamino)cyclohexyl]oxy}-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-{4-(2,4-difluorophenoxy)-3-[1-methyl-6-oxo-4-(piperidin-4-yloxy)-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-{1-methyl-4-[(1-methylpyrrolidin-3-yl)methoxy]-6-oxo-1,6-dihydropyridin-3-yl}phenyl]ethanesulfonamide;

tert-butyl 4-{[(5-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)oxy]methyl}piperidine-1-carboxylate;

tert-butyl 6-[(5-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)amino]phenyl}-1-methyl-2-oxo-1,2-dihydropyridin-4-yl)oxy]-2-azaspiro[3.3]heptane-2-carboxylate;

N-{3-[4-(2-azaspiro[3.3]hept-6-yloxy)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]-4-(2,4-difluorophenoxy)phenyl}ethanesulfonamide;

5-{2-[(cyclopropylmethyl)amino]-5-(methylsulfonyl)phenyl}-4-[(E)-2-ethoxyethenyl]-1-methylpyridin-2(1H)-one;

N-[3-(4-{[4-(diethylamino)but-2-yn-1-yl]oxy}-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(2,4-difluorophenoxy)phenyl]ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-{1-methyl-6-oxo-4-[(1E)-prop-1-en-1-yl]-1,6-dihydropyridin-3-yl}phenyl]ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-{1-methyl-4-[4-(4-methylpiperazin-1-yl)phenyl]-6-oxo-1,6-dihydropyridin-3-yl}phenyl]ethanesulfonamide;

N-{4-(2,4-difluorophenoxy)-3-[4-(2-hydroxyphenyl)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-{4-(2,4-difluorophenoxy)-3-[4-(4-formylthiophen-3-yl)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-{4-[(1,1-$^{2}H_{2}$)ethyloxy]-1-methyl-6-oxo-1,6-dihydropyridin-3-yl}phenyl]ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-{4-[($^{2}H_{5}$)ethyloxy]-1-methyl-6-oxo-1,6-dihydropyridin-3-yl}phenyl]ethanesulfonamide;

N-[3-{4-[(2,2-difluoro-1-methylcyclopropyl)methoxy]-1-methyl-6-oxo-1,6-dihydropyridin-3-yl}-4-(2,4-difluorophenoxy)phenyl]ethanesulfonamide;

N-{4-[2-fluoro-4-(oxetan-3-yloxy)phenoxy]-3-[1-methyl-4-(oxetan-3-yloxy)-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

5-{2-[(cyclopropylmethyl)amino]-5-(methylsulfonyl)phenyl}-4-[(Z)-2-ethoxyethenyl]-1-methylpyridin-2(1H)-one;

ethyl {5-[2-(cyclopropylmethoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-2-oxo-1,2-dihydropyridin-3-yl}carbamate;

N-{5-[2-(cyclopropylmethoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-2-oxo-1,2-dihydropyridin-3-yl}methanesulfonamide;

5-{2-[(cyclopropylmethyl)amino]-5-(methylsulfonyl)phenyl}-4-ethoxy-1-methylpyridin-2(1H)-one;

5-{2-[(cyclopropylmethyl)amino]-5-(methylsulfonyl)phenyl}-4-[(3-hydroxy-2,3-dimethylbutan-2-yl)oxy]-1-methylpyridin-2(1H)-one;

N-{4-(2,4-difluorophenoxy)-3-[1-methyl-4-(1-methyl-1H-pyrazol-4-yl)-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]naphthalene-1-sulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]benzenesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(1-methyl-4-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-{4-(2,4-difluorophenoxy)-3-[1-methyl-6-oxo-4-(1H-pyrazol-1-yl)-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-4-(propan-2-yl)benzenesulfonamide;

4-chloro-N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-2-fluorobenzenesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]propane-1-sulfonamide;

1-(2-chloro-5-fluorophenyl)-N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]methanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-1-(2-fluorophenyl)methanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(5-fluoro-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-[3-{4-[(cyclopropylmethyl)amino]-1-methyl-6-oxo-1,6-dihydropyridin-3-yl}-4-(2,4-difluorophenoxy)phenyl]ethanesulfonamide;

5-[2-(cyclopropylmethoxy)-6-methylphenyl]-1-methylpyridin-2(1H)-one;

3-amino-5-[2-(cyclopropylmethoxy)-5-(ethylsulfonyl)phenyl]-1-methylpyridin-2(1H)-one;

N-[4-(4-cyanophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(1-methyl-6-oxo-4-propyl-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

5-{5-(ethylsulfonyl)-2-[(cis-4-methoxy-4-methylcyclohexyl)oxy]phenyl}-1-methylpyridin-2(1H)-one;

N-{5-[2-(cyclopropylmethoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-2-oxo-1,2-dihydropyridin-3-yl}acetamide;

N-{3-[4-(cyclopropylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]-4-(2,4-difluorophenoxy)phenyl}ethanesulfonamide;

N-{4-(2,4-difluorophenoxy)-3-[4-(ethylamino)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

5-[2-(2,4-difluorophenoxy)-5-(propan-2-ylsulfonyl)phenyl]-1-methylpyridin-2(1H)-one;

N-[4-(cyclopropylmethoxy)-2-methyl-3-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-[4-(cyclopropylmethoxy)-2-methyl-5-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-{3-[4-(cyclobutyloxy)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]-4-(2,4-difluorophenoxy)phenyl}ethanesulfonamide;

5-{2-[(2,2-difluorocyclopropyl)methoxy]-5-(ethylsulfonyl)phenyl}-4-ethoxy-1-methylpyridin-2(1H)-one;

5-[2-(2,4-difluorophenoxy)-5-(propan-2-ylsulfonyl)phenyl]-4-ethoxy-1-methylpyridin-2(1H)-one;

5-{2-(2,4-difluorophenoxy)-5-[(methylsulfonyl)methyl]phenyl}-4-ethoxy-1-methylpyridin-2(1H)-one;

5-[5-(cyclopropylsulfonyl)-2-(2,4-difluorophenoxy)phenyl]-4-ethoxy-1-methylpyridin-2(1H)-one;

N-{4-(2,4-difluorophenoxy)-3-[4-(3-hydroxy-3-methylbutoxy)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

5-[2-(cyclopropylamino)-5-(ethylsulfonyl)phenyl]-4-ethoxy-1-methylpyridin-2(1H)-one;

N-{4-(4-cyanophenoxy)-3-[1-methyl-6-oxo-4-(2,2,2-trifluoroethoxy)-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

5-[2-(2,4-difluorophenoxy)-5-(ethylsulfonyl)phenyl]-4-ethoxy-1-methylpyridin-2(1H)-one;

N-{4-(2,4-difluorophenoxy)-3-[4-(2-hydroxy-2-methylpropoxy)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

4-ethoxy-5-{5-(ethylsulfonyl)-2-[4-(trifluoromethoxy)phenoxy]phenyl}-1-methylpyridin-2(1H)-one;

4-[2-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(ethylsulfonyl)phenoxy]benzonitrile;

5-{2-(2,4-difluorophenoxy)-5-[(ethylsulfonyl)methyl]phenyl}-4-ethoxy-1-methylpyridin-2(1H)-one;

5-{2-(2,4-difluorophenoxy)-5-[2-(ethylsulfonyl)propan-2-yl]phenyl}-4-ethoxy-1-methylpyridin-2(1H)-one;

N-[4-(cyclopropylmethoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

4-chloro-5-[2-(2,4-difluorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methylpyridin-2(1H)-one;

N-[4-(2-cyclopropylethoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-[4-(cyclobutyloxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-{4-[(4,4-difluorocyclohexyl)oxy]-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl}ethanesulfonamide;

N-{3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-[4-(trifluoromethyl)phenoxy]phenyl}ethanesulfonamide;

N-{3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-[4-(trifluoromethoxy)phenoxy]phenyl}ethanesulfonamide;

ethyl 4-{2-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-[(ethylsulfonyl)amino]phenoxy}piperidine-1-carboxylate;

N-{4-[(1-acetylpiperidin-4-yl)oxy]-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl}ethanesulfonamide;

N-{3-[4-(1-benzyl-1H-pyrazol-4-yl)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]-4-(2,4-difluorophenoxy)phenyl}ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-{1-methyl-4-[1-(2-methylpropyl)-1*H*-pyrazol-4-yl]-6-oxo-1,6-dihydropyridin-3-yl}phenyl]ethanesulfonamide;

N-{4-(2,4-difluorophenoxy)-3-[4-(furan-2-yl)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-{4-(2,4-difluorophenoxy)-3-[4-(furan-3-yl)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-[4-(2,3-dihydro-1H-inden-2-yloxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

tert-butyl (trans-4-{2-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-[(ethylsulfonyl)amino]phenoxy}cyclohexyl)carbamate;

N-[3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(4-fluorophenoxy)phenyl]ethanesulfonamide;

5-[2-(cyclopropylmethoxy)-5-(2,3-dihydro-1H-indol-1-ylsulfonyl)phenyl]-4-ethoxy-1-methylpyridin-2(1H)-one;

4-[2-(2,4-difluorophenoxy)-5-(ethylsulfonyl)phenyl]-1-methyl-5-(2,2,2-trifluoroethoxy)pyridin-2(1H)-one;

N-{4-(2,4-difluorophenoxy)-3-[1-methyl-6-oxo-4-(piperidin-4-ylmethoxy)-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-[4-(4-chlorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-[4-(3,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-[3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(3,4,5-trifluorophenoxy)phenyl]ethanesulfonamide;

N-[4-(4-chloro-2-fluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-[4-(4-chloro-2,6-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-[3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(pyridin-3-yloxy)phenyl]ethanesulfonamide;

5-[5-amino-2-(2,4-difluorophenoxy)phenyl]-4-ethoxy-1-methylpyridin-2(1H)-one;

N-{4-(2,4-difluorophenoxy)-3-[1-methyl-4-(5-methylthiophen-2-yl)-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-[4-(4-cyano-2-fluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

5-{2-[(2,4-difluorobenzyl)amino]-5-(methylsulfonyl)phenyl}-4-ethoxy-1-methylpyridin-2(1H)-one;

N-[3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-({1-[4-(trifluoromethyl)phenyl]piperidin-4-yl}oxy)phenyl]ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-1,3-thiazole-5-carboxamide;

2,5-dichloro-N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]benzamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-4-(propan-2-yl)benzamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-5-methylpyrazine-2-carboxamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]pyridine-2-carboxamide;

4-tert-butyl-N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]benzenesulfonamide;

2,4-dichloro-N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]benzenesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]naphthalene-2-sulfonamide;

5-[2-(2,4-difluorophenoxy)-5-(2,3-dihydro-1H-indol-1-ylsulfonyl)phenyl]-4-ethoxy-1-methylpyridin-2(1H)-one; and

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]-N-methyl-1-phenylmethanesulfonamide.

28. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein said compound is selected from the group consisting of:

2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

6-[2-(benzyloxy)phenyl]-2-methylpyridazin-3(2H)-one;

-[2-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)phenoxy]benzonitrile;

6-[2-(cyclopentyloxy)phenyl]-2-methylpyridazin-3(2H)-one;

6-[2-(4-hydroxybutoxy)phenyl]-2-methylpyridazin-3(2H)-one;

2-methyl-6-[2-(pyridin-2-yloxy)phenyl]pyridazin-3(2H)-one;

2-methyl-6-{2-[4-(trifluoromethyl)phenoxy]phenyl}pyridazin-3(2H)-one;

2-methyl-6-{2-[4-(methylsulfonyl)phenoxy]phenyl}pyridazin-3(2H)-one;

2-methyl-6-(5-nitro-2-phenoxyphenyl)pyridazin-3(2H)-one;

6-(5-amino-2-phenoxyphenyl)-2-methylpyridazin-3(2H)-one;

4-methyl-N-[3-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-4-phenoxyphenyl]benzenesulfonamide;

N-[3-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-4-phenoxyphenyl]acetamide;

3-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-4-phenoxybenzonitrile;

3-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-4-phenoxybenzamide;

3-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-4-phenoxybenzoic acid;

N-[3-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-4-phenoxybenzyl]acetamide;

2,2,2-trifluoro-N-[3-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-4-phenoxybenzyl]acetamide;

5-methoxy-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

N-[3-(4-methoxy-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)phenyl]methanesulfonamide;

6-(5-amino-2-phenoxyphenyl)-5-methoxy-2-methylpyridazin-3(2H)-one;

N-[3-(4-methoxy-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-4-phenoxyphenyl]acetamide;

N-[3-(4-methoxy-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-4-phenoxyphenyl]methanesulfonamide;

N-[3-(4-methoxy-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-4-phenoxyphenyl]-N-methylmethanesulfonamide;

N-[3-(4-methoxy-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-4-phenoxyphenyl]propane-1-sulfonamide;

2,2,2-trifluoro-N-[3-(4-methoxy-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-4-phenoxyphenyl]ethanesulfonamide;

N-[3-(4-methoxy-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-4-phenoxyphenyl]cyclopentanesulfonamide;

N-[3-(4-methoxy-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-4-phenoxyphenyl]-1-phenylmethanesulfonamide;

3,3,3-trifluoro-N-[3-(4-methoxy-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-4-phenoxyphenyl]propane-1-sulfonamide;

Ethyl [3-(4-methoxy-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-4-phenoxyphenyl]carbamate;

1-ethyl-3-[3-(4-methoxy-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-4-phenoxyphenyl]urea;

N'-[3-(4-methoxy-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)-4-phenoxyphenyl]-N,N-dimethylsulfuric diamide;

4-[2-(4-methoxy-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)phenoxy]benzonitrile;

6-[2-(4-fluorophenoxy)phenyl]-5-methoxy-2-methylpyridazin-3(2H)-one;

6-[2-(3-chloro-4-fluorophenoxy)phenyl]-5-methoxy-2-methylpyridazin-3(2H)-one;

5-methoxy-6-[2-(4-methoxyphenoxy)phenyl]-2-methylpyridazin-3(2H)-one;

6-[2-(3-fluorophenoxy)phenyl]-5-methoxy-2-methylpyridazin-3(2H)-one;

6-[2-(4-chlorophenoxy)phenyl]-5-methoxy-2-methylpyridazin-3(2H)-one;

methyl {[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]oxy}acetate;

6-[2-(cyclohexyloxy)phenyl]-5-methoxy-2-methylpyridazin-3(2H)-one;

5-methoxy-2-methyl-6-[2-(pyridin-2-ylmethoxy)phenyl]pyridazin-3(2H)-one;

6-[2-(1H-indazol-5-ylmethoxy)phenyl]-5-methoxy-2-methylpyridazin-3(2H)-one;

6-[2-(2-cyclohexylethoxy)phenyl]-5-methoxy-2-methylpyridazin-3(2H)-one;

tert-butyl 4-{[2-(4-methoxy-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)phenoxy]methyl}piperidine-1-carboxylate;

5-methoxy-2-methyl-6-[2-(piperidin-4-ylmethoxy)phenyl]pyridazin-3(2H)-one;

5-methoxy-2-methyl-6-[2-(pyridin-4-ylmethoxy)phenyl]pyridazin-3(2H)-one;

6-[2-(cyclopentylmethoxy)phenyl]-5-methoxy-2-methylpyridazin-3(2H)-one;

5-methoxy-2-methyl-6-[2-(tetrahydro-2H-pyran-4-ylmethoxy)phenyl]pyridazin-3(2H)-one;

methyl 1-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]pyrrolidine-3-carboxylate;

Ethyl 1-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]pyrrolidine-3-carboxylate;

methyl N-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]glycinate;

2-methyl-5-(4-methyl-3-oxopiperazin-1-yl)-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

6-(biphenyl-2-yl)-2-methylpyridazin-3(2H)-one;

2'-(1-methyl-6-oxo-1,6-dihydropyridazin-3-yl)biphenyl-3-carbonitrile;

5-(2-fluoropyridin-4-yl)-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

2-methyl-5-(2-oxo-1,2-dihydropyridin-4-yl)-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

2-methyl-5-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

5-(2-methoxypyridin-4-yl)-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

N-{3-[4-(2-methoxypyridin-4-yl)-1-methyl-6-oxo-1,6-dihydropyridazin-3-yl]-4-phenoxyphenyl}methanesulfonamide;

Ethyl 3-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzoate;

2-methyl-5-{3-[(4-methylpiperazin-1-yl)methyl]phenyl}-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

2-methyl-5-{4-[(4-methylpiperazin-1-yl)methyl]phenyl}-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

N-[3-(1-methyl-4-{4-[(4-methylpiperazin-1-yl)methyl]phenyl}-6-oxo-1,6-dihydropyridazin-3-yl)-4-phenoxyphenyl]methanesulfonamide;

N-{3-[1-methyl-4-(4-methylphenyl)-6-oxo-1,6-dihydropyridazin-3-yl]-4-phenoxyphenyl}methanesulfonamide;

5-(3-amino-4-methylphenyl)-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzaldehyde;

2-methyl-5-[4-(morpholin-4-ylmethyl)phenyl]-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

2-methyl-6-(2-phenoxyphenyl)-5-[4-(piperidin-1-ylmethyl)phenyl]pyridazin-3(2H)-one;

2-methyl-5-{4-[(4-methylpiperidin-1-yl)methyl]phenyl}-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

5-{4-[(diethylamino)methyl]phenyl}-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

2-methyl-6-(2-phenoxyphenyl)-5-[4-(piperazin-1-ylmethyl)phenyl]pyridazin-3(2H)-one;

2-methyl-6-(2-phenoxyphenyl)-5-[4-(pyrrolidin-1-ylmethyl)phenyl]pyridazin-3(2H)-one;

5-[4-(1-hydroxypropyl)phenyl]-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

5-[4-(1-hydroxy-2-methylpropyl)phenyl]-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

5-{4-[cyclopentyl(hydroxy)methyl]phenyl}-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

5-[4-(1-hydroxyethyl)phenyl]-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

5-{4-[hydroxy(phenyl)methyl]phenyl}-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

5-[4-(1-hydroxybut-3-en-1-yl)phenyl]-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

5-[4-(hydroxymethyl)phenyl]-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

5-[4-(methoxymethyl)phenyl]-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzyl acetate;

tert-butyl 4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]-3,6-dihydropyridine-1(2H)-carboxylate;

2-methyl-6-(2-phenoxyphenyl)-5-(1,2,3,6-tetrahydropyridin-4-yl)pyridazin-3(2H)-one;

2-methyl-5-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

5-(1-acetyl-1,2,3,6-tetrahydropyridin-4-yl)-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

2-methyl-5-[1-(methylsulfonyl)-1,2,3,6-tetrahydropyridin-4-yl]-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

tert-butyl 4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]piperidine-1-carboxylate;

2-methyl-6-(2-phenoxyphenyl)-5-(piperidin-4-yl)pyridazin-3(2H)-one;

2-methyl-5-(1-methylpiperidin-4-yl)-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

5-(1-acetylpiperidin-4-yl)-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

2-methyl-5-[1-(methylsulfonyl)piperidin-4-yl]-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

2-methyl-5-[4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

methyl 3-{4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]phenyl}propanoate;

5-(4-benzylphenyl)-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

{4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]phenyl}acetonitrile;

5-[4-(5,6-dihydro-4H-1,3-oxazin-2-yl)phenyl]-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

2-methyl-5-[4-(2-methylpropyl)phenyl]-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

Ethyl {4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]phenyl}acetate;

N-{4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzyl}methanesulfonamide;

N-{4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzyl}acetamide;

N-(2-{4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]phenyl}ethyl)acetamide;

5-[4-(3-hydroxypropyl)phenyl]-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

methyl 4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzoate;

2-methyl-5-(1-methyl-1H-pyrazol-4-yl)-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

2-methyl-6-(2-phenoxyphenyl)-5-(pyridin-4-yl)pyridazin-3(2H)-one;

N-{4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]phenyl}acetamide;

N-{3-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]phenyl}acetamide;

5-(4-ethoxy-3-fluorophenyl)-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

N,N-dimethyl-4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzamide;

N,N-dimethyl-3-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzamide;

2-methyl-5-[3-(2-methylpropoxy)phenyl]-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

5-[3-fluoro-4-(propan-2-yloxy)phenyl]-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzenesulfonamide;

5-(1-benzyl-1H-pyrazol-4-yl)-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

N-cyclopropyl-4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzamide;

5-(3,5-dimethyl-1H-pyrazol-4-yl)-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

5-(6-methoxypyridin-3-yl)-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;
5-(4-ethoxyphenyl)-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;
5-(isoquinolin-4-yl)-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;
N-{4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]phenyl}methanesulfonamide;
N-{3-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]phenyl}methanesulfonamide;
N-{5-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]pyridin-3-yl}acetamide;
N-methyl-5-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]pyridine-3-carboxamide;
2-methyl-6-(2-phenoxyphenyl)-5-[6-(propan-2-yloxy)pyridin-3-yl]pyridazin-3(2H)-one;
5-(3-acetyl-2-fluorophenyl)-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;
5-(2,6-dimethoxypyridin-3-yl)-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;
methyl 2-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzoate;
N-methyl-4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzamide;
N-methyl-3-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzamide;
2-methyl-5-[1-(3-methylbutyl)-1H-pyrazol-4-yl]-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;
2-methyl-6-(2-phenoxyphenyl)-5-[2-(propan-2-yloxy)pyridin-3-yl]pyridazin-3(2H)-one;
5-(1,3-benzothiazol-5-yl)-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;
5-(5-acetyl-2-fluorophenyl)-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;
5-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;
5-[3-(1-methoxyethyl)phenyl]-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;
5-[4-(1-methoxyethyl)phenyl]-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;
5-(3-ethoxy-2-fluorophenyl)-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;
5-(2,1,3-benzothiadiazol-5-yl)-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;
5-[5-(benzylamino)pyridin-3-yl]-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;
2-methyl-5-[3-(morpholin-4-yl)phenyl]-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

2-methyl-6-(2-phenoxyphenyl)-5-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]pyridazin-3(2H)-one;

2-methyl-5-[3-(morpholin-4-ylmethyl)phenyl]-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

2-methyl-6-(2-phenoxyphenyl)-5-[3-(thiomorpholin-4-ylcarbonyl)phenyl]pyridazin-3(2H)-one;

5-[5-(cyclopentylamino)pyridin-3-yl]-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

N-cyclopropyl-5-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]pyridine-3-carboxamide;

N-cyclopentyl-5-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]pyridine-3-carboxamide;

N,N-diethyl-3-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzenesulfonamide;

2-methyl-5-[4-(morpholin-4-ylcarbonyl)phenyl]-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

N-cyclohexyl-N-methyl-3-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzamide;

2-methyl-5-[4-(morpholin-4-yl)phenyl]-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

N-[3-(dimethylamino)propyl]-4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzamide;

2-methyl-6-(2-phenoxyphenyl)-5-[6-(piperazin-1-yl)pyridin-3-yl]pyridazin-3(2H)-one;

3-fluoro-N,N-dimethyl-5-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzamide;

2-methyl-5-[2-(morpholin-4-yl)pyridin-4-yl]-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

2-methyl-5-{3-[(4-methylpiperidin-1-yl)carbonyl]phenyl}-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

2-fluoro-N,N-dimethyl-5-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzamide;

2-methyl-6-(2-phenoxyphenyl)-5-[3-(pyrrolidin-1-ylsulfonyl)phenyl]pyridazin-3(2H)-one;

2-methyl-6-(2-phenoxyphenyl)-5-[3-(piperidin-1-ylcarbonyl)phenyl]pyridazin-3(2H)-one;

N,N-diethyl-4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzamide;

N-methyl-4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzenesulfonamide;

N,N-diethyl-3-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzamide;

2-methyl-5-[4-(4-methylpiperazin-1-yl)phenyl]-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

2-methyl-5-(6-{[2-(morpholin-4-yl)ethyl]amino}pyridin-3-yl)-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

N-[3-(dimethylamino)propyl]-3-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzamide;

5-[6-(benzylamino)pyridin-3-yl]-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

N-(2-cyanoethyl)-4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzamide;

2-methyl-5-[5-methyl-6-(morpholin-4-yl)pyridin-3-yl]-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

N,N-diethyl-3-fluoro-5-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzamide;

N-tert-butyl-4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzamide;

N-cyclopentyl-4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzamide;

4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]-N-(2-methylpropyl)benzamide;

N-(3-methoxypropyl)-4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzamide;

2-methyl-5-{1-[2-(morpholin-4-yl)ethyl]-1H-pyrazol-4-yl}-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

N-(2-methoxyethyl)-4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzamide;

2-methyl-5-[2-(4-methylpiperazin-1-yl)pyridin-4-yl]-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

2-methyl-5-[3-(morpholin-4-ylcarbonyl)phenyl]-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

2-methyl-5-[3-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

N-cyclopropyl-3-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzamide;

2-methyl-6-(2-phenoxyphenyl)-5-[4-(pyrrolidin-1-ylsulfonyl)phenyl]pyridazin-3(2H)-one;

2-methyl-5-[6-(morpholin-4-yl)pyridin-3-yl]-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

2-methyl-6-(2-phenoxyphenyl)-5-{4-[4-(propan-2-yl)piperazin-1-yl]phenyl}pyridazin-3(2H)-one;

N,N-diethyl-2-fluoro-5-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzamide;

N-benzyl-4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzamide;

2-methyl-6-(2-phenoxyphenyl)-5-[4-(pyrrolidin-1-ylcarbonyl)phenyl]pyridazin-3(2H)-one;

2-methyl-6-(2-phenoxyphenyl)-5-[6-(piperidin-1-yl)pyridin-3-yl]pyridazin-3(2H)-one;

N-cyclohexyl-4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzamide;

N-[2-(dimethylamino)ethyl]-3-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzamide;

2-methyl-6-(2-phenoxyphenyl)-5-{4-[(phenylamino)methyl]phenyl}pyridazin-3(2H)-one;

2-methyl-5-[2-(4-methylpiperazin-1-yl)pyrimidin-5-yl]-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

methyl {4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]phenyl}acetate;

5-(5-ethoxypyridin-3-yl)-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

2-methyl-5-[4-(methylamino)phenyl]-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

5-[2-(dimethylamino)pyrimidin-5-yl]-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

{3-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]phenyl}acetonitrile;

2-methyl-5-(1-methyl-1H-pyrrol-2-yl)-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

2-methyl-6-(2-phenoxyphenyl)-5-(pyridin-3-yl)pyridazin-3(2H)-one;

2-methyl-5-(6-methylpyridin-3-yl)-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

5-(3-methoxyphenyl)-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

2-methyl-5-(4-methyl-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-7-yl)-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

5-(4-fluoro-3-methoxyphenyl)-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

5-(2-aminopyridin-4-yl)-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

5-(3-acetylphenyl)-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

N-ethyl-4-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]benzamide;

5-(3-fluoro-4-methoxyphenyl)-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

5-(1,5-dimethyl-1H-pyrazol-4-yl)-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

2-methyl-5-(2-methylpyridin-4-yl)-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

2-methyl-5-[1-(2-methylpropyl)-1H-pyrazol-4-yl]-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

2-methyl-5-(4-methylpyridin-3-yl)-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

2-methyl-5-(1-methyl-1H-indol-5-yl)-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

5-[3-(dimethylamino)phenyl]-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

5-(2-fluoro-5-methoxyphenyl)-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

2-methyl-5-(5-methylfuran-2-yl)-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

5-(1-ethyl-1H-pyrazol-4-yl)-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

5-(3-methoxypyridin-4-yl)-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

2-methyl-5-(1-methyl-1H-indol-2-yl)-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

N,N-dimethyl-5-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]pyridine-3-carboxamide;

5-[5-(dimethylamino)pyridin-3-yl]-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

5-butyl-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

methyl 1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazine-4-carboxylate;

methyl (2E)-3-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]prop-2-enoate;

methyl 3-[1-methyl-6-oxo-3-(2-phenoxyphenyl)-1,6-dihydropyridazin-4-yl]propanoate;

5-acetyl-2-methyl-6-(2-phenoxyphenyl)pyridazin-3(2H)-one;

6-(2-benzylphenyl)-2-methylpyridazin-3(2H)-one;

N-[4-(2,4-difluorophenoxy)-3-(4-ethoxy-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-{1-methyl-4-[2-(morpholin-4-yl)ethoxy]-6-oxo-1,6-dihydropyridin-3-yl}phenyl]ethanesulfonamide;

N-(3-(4-(cyclopropylmethoxy)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-(2,4-difluorophenoxy)phenyl)ethanesulfonamide;

N-(4-(2,4-difluorophenoxy)-3-(4-(2-(dimethylamino)ethoxy)-1-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl)ethanesulfonamide;

N-{4-(2,4-difluorophenoxy)-3-[1-methyl-6-oxo-4-(propan-2-yloxy)-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-{4-(2,4-difluorophenoxy)-3-[1-methyl-4-(2-methylpropoxy)-6-oxo-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-{4-(2,4-difluorophenoxy)-3-[1-methyl-6-oxo-4-(tetrahydrofuran-3-ylmethoxy)-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(1-methyl-6-oxo-4-propoxy-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide; and

N-{4-(2,4-difluorophenoxy)-3-[1-methyl-6-oxo-4-(2,2,2-trifluoroethoxy)-1,6-dihydropyridin-3-yl]phenyl}ethanesulfonamide.

29. The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein said compound is selected from the group consisting of:

3-methyl-5-(2-phenoxyphenyl)pyridin-2(1H)-one;

N-[3-(5-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-phenoxyphenyl]methanesulfonamide;

N-[3-(5-methyl-6-oxo-1,6-dihydropyridin-3-yl)-4-phenoxyphenyl]acetamide;

N-[4-(2,4-difluorophenoxy)-3-(5-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]methanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(5-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]ethanesulfonamide;

N-[4-(2,4-difluorophenoxy)-3-(5-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl]acetamide;

N-{4-[(4,4-difluorocyclohexyl)oxy]-3-(5-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl}methanesulfonamide; and

N-{4-[(4,4-difluorocyclohexyl)oxy]-3-(5-methyl-6-oxo-1,6-dihydropyridin-3-yl)phenyl}ethanesulfonamide.

30. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) according to claim 1, or a pharmaceutically acceptable acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.

31. Use of a therapeutically effective amount of a compound of formula (I) according to claim 1, or a pharmaceutically acceptable acceptable salt thereof, in the manufacture of a medicament for treating cancer, wherein the medicament is to be administered to a subject in need thereof.

32. The use of claim 31, wherein the cancer is selected from the group consisting of: acoustic neuroma, acute leukemia, acute lymphocytic leukemia, acute myelocytic leukemia (monocytic, myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute t-cell leukemia, basal cell carcinoma, bile duct carcinoma, bladder cancer, brain cancer, breast cancer, bronchogenic carcinoma, cervical cancer, chondrosarcoma, chordoma, choriocarcinoma, chronic leukemia, chronic lymphocytic leukemia, chronic myelocytic (granulocytic) leukemia, chronic myelogenous leukemia, colon cancer, colorectal cancer, craniopharyngioma, cystadenocarcinoma, diffuse large B-cell lymphoma, dysproliferative changes (dysplasias and metaplasias), embryonal carcinoma, endometrial cancer, endotheliosarcoma, ependymoma, epithelial carcinoma, erythroleukemia, esophageal cancer, estrogen-receptor positive breast cancer, essential thrombocythemia, Ewing's tumor, fibrosarcoma, follicular lymphoma, germ cell testicular cancer, glioma, glioblastoma, gliosarcoma, heavy chain disease, hemangioblastoma, hepatoma, hepatocellular cancer, hormone insensitive prostate cancer, leiomyosarcoma, leukemia, liposarcoma, lung cancer, lymphagioendotheliosarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma (Hodgkin's and non-Hodgkin's), malignancies and hyperproliferative disorders of the bladder, breast, colon, lung, ovaries, pancreas, prostate, skin and uterus, lymphoid malignancies of T-cell or B-cell origin, leukemia, lymphoma, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myelogenous

leukemia, myeloma, myxosarcoma, neuroblastoma, NUT midline carcinoma (NMC), non-small cell lung cancer, oligodendroglioma, oral cancer, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinomas, papillary carcinoma, pinealoma, polycythemia vera, prostate cancer, rectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, sebaceous gland carcinoma, seminoma, skin cancer, small cell lung carcinoma, solid tumors (carcinomas and sarcomas), small cell lung cancer, stomach cancer, squamous cell carcinoma, synovioma, sweat gland carcinoma, thyroid cancer, Waldenström's macroglobulinemia, testicular tumors, uterine cancer and Wilms' tumor.

33. The use of claim 32, wherein a therapeutically effective amount of at least one additional therapeutic agent is to be further administered.

34. Use of a therapeutically effective amount of a compound of formula (I) according to claim 1, or a pharmaceutically acceptable acceptable salt thereof, in the manufacture of a medicament for treating a disease or condition , wherein said disease or condition is selected from the group consisting of: Addison's disease, acute gout, ankylosing spondylitis, asthma, atherosclerosis, Behcet's disease, bullous skin diseases, chronic obstructive pulmonary disease (COPD), Crohn's disease,dermatitis, eczema,giant cell arteritis, glomerulonephritis, hepatitis, hypophysitis, inflammatory bowel disease,), Kawasaki disease, lupus nephritis, multiple sclerosis, myocarditis,myositis, nephritis, organ transplant rejection, osteoarthritis, pancreatitis, pericarditis, Polyarteritis nodosa, pneumonitis, primary biliary cirrhosis, psoriasis, psoriatic arthritis, rheumatoid arthritis, scleritis, sclerosing cholangitis, sepsis systemic lupus erythematosus, Takayasu's Arteritis, toxic shock, thyroiditis, type I diabetes, ulcerative colitis, uveitis, vitiligo, vasculitis, and Wegener's granulomatosis, wherein the medicament is to be administered to a subject in need thereof.

35. The use of claim 34, wherein a therapeutically effective amount of at least one additional therapeutic agent is to be further administered.

36. Use of a therapeutically effective amount of a compound of formula (I) according to claim 1, or a pharmaceutically acceptable acceptable salt thereof, in the manufacture of a medicament for treating AIDS, wherein the medicament is to be administered to a subject in need thereof.

37. The use of claim 36, wherein a therapeutically effective amount of at least one additional therapeutic agent is to be further administered.

38. Use of a therapeutically effective amount of a compound of formula (I) according to claim 1, or a pharmaceutically acceptable acceptable salt thereof, in the manufacture of a medicament for treating obesity, wherein the medicament is to be administered to a subject in need thereof.

39. The use of claim 38, wherein a therapeutically effective amount of at least one additional therapeutic agent is to be further administered.

40. Use of a therapeutically effective amount of a compound of formula (I) according to claim 1, or a pharmaceutically acceptable acceptable salt thereof, in the manufacture of a medicament for treating type II diabetes, wherein the medicament is to be administered to a subject in need thereof.

41. The use of claim 40, wherein a therapeutically effective amount of at least one additional therapeutic agent is to be further administered.

42. Use of a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating an acute kidney disease or condition, wherein said acute kidney disease or condition is selected from the group consisting of: ischemia-reperfusion induced kidney disease, cardiac and major surgery induced kidney disease, percutaneous coronary intervention induced kidney disease, radio-contrast agent induced kidney disease, sepsis induced kidney disease, pneumonia induced kidney disease, and drug toxicity induced kidney disease, wherein the medicament is to be administered to a subject in need thereof.

43. The use of claim 42, wherein a therapeutically effective amount of at least one additional therapeutic agent is to be further administered.

44. Use of a therapeutically effective amount of a compound of claim 1 or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for treating a chronic kidney disease or condition, wherein said disease or condition is selected from the group consisting of: diabetic nephropathy, hypertensive nephropathy, HIV-associated nephropathy, glomerulonephritis, lupus nephritis, IgA nephropathy, focal segmental glomerulosclerosis, membranous glomerulonephritis, minimal change disease, polycystic kidney disease and tubular interstitial nephritis, wherein the medicament is to be administered to a subject in need thereof.

45. The use of claim 44, wherein a therapeutically effective amount of at least one additional therapeutic agent is to be further administered.